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Sickle cell disease (SCD) is a genetic hemoglobinopathy that has grown into a global health 
concern. While the advances in medical treatment and management of SCD during childhood 
have drastically improved the overall survival of children, the transition from pediatric to adult 
services is significantly inadequate in comparison. Life expectancies of patients with SCD in first 
world countries such as the United States are shortened to averages of 42 and 48 years for men 
and women, respectively. Despite the increasing number of people living with SCD, remarkably, 
few detailed studies have described the clinical course and complications of the disease over 
time. Interrupted tissue perfusion and vaso-occlusion by rigid sickle red blood cells (RBC) are 
considered the primary pathological mechanisms, however little is known about how SCD 
influences the physiology of surviving cells and tissue. Hemolysis, which is traditionally viewed 
as a secondary contributor to the sickle pathology, not only initiates and propagates occlusive 
crises, but the resulting chronic systemic oxidative stress may play a role in altering organ 
function. Asymptomatic vascular damage begins years before clinical symptoms manifest, at 
which point the damage is irreversible and progresses throughout life until multi-organ occurs. 
Bone is highly susceptible to oxidative stress and damage; however, the impact of SCD on bone 
health is significantly under-investigated despite its importance in maintaining overall health. 
The objective of this thesis was to characterize the pathophysiology of SCD on bone tissue 
growth and development. Our approach utilizing the Townes transgenic sickle mouse model 
allows for native bone degeneration to be thoroughly examined longitudinally at the macro- and 
microscopic level, which is clinically unfeasible. The theoretical and clinical significance 
accrued across this thesis will address the gaps in knowledge regarding the role of sickle RBC 
hemolysis in tissue degeneration, the onset and progression of sickle osteonecrosis, gender 
differences in sickle pathology, the influence of chronic oxidative stress on bone cell physiology, 
as well as the benefits of antioxidant therapies on sickle bone quality. This thesis will serve as 
the foundation for the future development and improvement of clinical diagnostic tools and non-
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Sickle cell disease (SCD) is a genetic hemoglobinopathy that was generally considered a 
concern only for people of African ancestry upon initial discovery. However, today SCD has 
grown into a global health concern with a growing number of cases being reported throughout 
South America, India, the Mediterranean, and the Middle East. While the advances in medical 
treatment and management of SCD during childhood, such as newborn screening and 
prophylactic vaccinations, have drastically improved the overall survival of children, the 
transition from pediatric to adult services is significantly inadequate in comparison. Life 
expectancies of patients with SCD in first world countries such as the United States are 
shortened to averages of 42 and 48 years for men and women, respectively. Despite the 
increasing number of people living with SCD, remarkably, few detailed studies have described 
the clinical course and complications of the disease in the body over time. Interrupted tissue 
perfusion and vascular occlusion by rigid sickle shaped red blood cells are considered the 
primary pathological mechanisms, however little is known about how SCD influences the 
physiology of the surviving cells and tissue. Hemolysis, which is traditionally viewed as a 
secondary contributor to the sickle pathology, not only initiates and propagates occlusive crises, 
but the resulting chronic systemic oxidative stress may play a role in altering organ function. 
Asymptomatic vascular damage begins years before clinical symptoms manifest, at which point 
the damage is irreversible and progresses throughout life until multi-organ failure occurs. Bone is 
highly susceptible to oxidative stress and damage; however, the impact of SCD on bone health is 
significantly under-investigated despite its importance in maintaining overall health.   
The objective of this thesis was to characterize the pathophysiology of SCD on bone 
tissue growth and development. Our approach utilizing the Townes transgenic sickle mouse 
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model allows for native bone degeneration to be thoroughly examined longitudinally at the 
macro- and microscopic level, which is clinically unfeasible. The theoretical and clinical 
significance accrued across this thesis will address the gaps in knowledge regarding (1) the role 
of sickle RBC hemolysis in tissue degeneration, (2) the onset and progression of sickle 
osteonecrosis, (3) gender differences in sickle pathology, (4) the influence of chronic oxidative 
stress on bone cell physiology, as well as (5) the benefits of antioxidant therapies on sickle bone 
quality. 
Overall, our work seeks to shift clinical research from solely focusing on pain 
management and curative therapies to maintaining tissue functionality by highlighting hemolysis 
derived oxidative stress as vital target of interest. This thesis will serve as the foundation for the 
future development and improvement of clinical diagnostic tools and non-erythroid tissue-based 





CHAPTER 1: GLOBAL MOTIVATION 
1.1. Global Motivation 
Sickle cell disease (SCD) is a hemoglobinopathy that was first described as an abnormal 
display of sickle shaped red blood cells (RBC) in the blood smear of a visiting dental student from 
Grenada named Walter Clement Noel in 1910 (Irons & Herrick 1910). Later it was discovered that 
SCD is an autosomal codominant point mutation originating from sub-Saharan Africa as an 
evolutionary agonist to combat Malaria; thereby classifying it as a condition that was a primary 
concern of those of African descent. However, today SCD has grown into a global health concern 
with a growing number of cases being reported throughout South America, India, and the Middle 
East. 
Unfortunately, the precise number of people living with SCD is unknown. This is largely 
due to the inability to account for the population of children born with SCD in resource-poor 
nations, which have the highest sickle birth frequencies as well as adolescent mortality. The World 
Health Organization estimates that there are 300,000 children born with SCD annually and nearly 
5% of the global population are heterozygous carriers of the sickle gene (Kato et al. 2018; Ryan et 
al. 2010; Figure 1.1). Moreover, the number of people with SCD is predicted to increase by 30% 





While the advances in medical treatment and management of SCD during childhood such 
as newborn screening, prophylactic vaccinations and antibiotics, and regular interactions with 
hematologists have drastically improved the overall survival of children with SCD, especially 
within first-world countries, the transition from pediatric to adult services is significantly 
inadequate in comparison (Emond et al. 1985; Hamideh et al. 2013). Life expectancies of patients 
with SCD are shortened at averages of 42 and 48 years for males and females in the United States, 
respectively (Platt, 1994; Figure 1.2). Despite the increasing number of people living with SCD, 
remarkably, few detailed studies have described the clinical course and complications of the 
disease on the body. 
Figure 1.1 - Number of newborns with sickle cell anemia in 2015. Birth rate expected to 
increase by 30% between 2010-2050. Reproduced with permission from Piel et al, 2017, 






Sickle literature can largely be classified either as clinical reports (i.e. patient education, 
case studies, and meta-analysis) or curative research (i.e. genetic engineering, improving stem 
transplantation, and preventing adhesion). Although interrupted tissue perfusion and end organ 
damage from sickle RBCs and vascular occlusion are considered the primary pathological 
mechanisms, little is known about how SCD influences the physiology of the surviving cells and 
tissue (Barabino et al., 2010; Rees et al., 2010). Hemolysis, which is traditionally viewed as a 
secondary contributor to sickle pathology, not only initiates and propagates occlusive crises, but 
the resulting chronic systemic oxidative stress may play a role in altering organ function (Kato et 
al., 2017).  
Figure 1.2 - The life expectancy of people with sickle-cell disease in the United 
States has increased due to medical advancements. Reprinted by permission 




1.2. Specific Aims 
The objective of this thesis was to characterize the pathophysiology of SCD on bone tissue 
growth and development. Our approach utilizing the Townes transgenic sickle mouse model 
allows for native bone degeneration to be thoroughly examined longitudinally at the macro- and 
microscopic level, which is clinically unfeasible. The theoretical and clinical significance accrued 
across this thesis will address the gaps in knowledge regarding (1) the role of sickle RBC hemolysis 
in tissue degeneration, (2) the onset and progression of sickle osteonecrosis, (3) gender differences 
in sickle pathology, (4) the influence of chronic oxidative stress on osteocyte physiology and 
integrity, as well as (5) the benefits of antioxidant therapies on sickle bone quality. This project’s 
objective was met with the following specific aims. 
1. Specific Aim 1: Determine the influence of SCD on bone microarchitecture and 
biomechanics. 
2. Specific Aim 2: Identify the role sex plays in the onset of sickle bone pathology. 
3. Specific Aim 3: Determine whether the Townes mouse model recapitulates the clinical 
observations of GLN therapy and assess tissue level implications via bone quality metrics. 
 
The completion of Aim 1 led to the first depiction of bone microarchitectural organization and its 
respective mechanics in SCD as well as the transition from a relatively normal phenotype during 
adolescence to diseased at skeletal maturity in both homozygous (SS) and heterozygous (AS) 
genotypes. The contribution of Aim 2 established the temporal and spatial onset of sickle bone 
degeneration in relation to the accumulation of hemolytic oxidative stress biomarkers. Moreover, 
highlighting the influence of oxidative stress from non-transfusional iron overload and progressive 
accumulation within tissues (specifically the liver and bone) leading to the gender dimorphic 
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manifestations of sickle bone. To our knowledge, this body of work is the first to study the 
relationship between liver physiology and bone development within SCD. The completion of Aim 
3 will be the first non-clinical trial study trying to define the therapeutic mechanism of L-glutamine 
in the management of SCD.  
Overall, our work seeks to shift clinical research from solely focusing on pain management 
and curative therapies to maintaining tissue functionality by highlighting hemolysis derived 
oxidative stress as the primary target of interest. This thesis will serve as the foundation for the 
development and improvement of clinical diagnostic tools and non-erythroid tissue-based 

















CHAPTER 2: LITERATURE REVIEW 
2.1. Sickle Cell Disease Background 
Sickle cell disease (SCD) is an inherited hemoglobinopathy due to a single point mutation 
in the β-hemoglobin gene that replaces the hydrophilic glutamic acid with a relatively hydrophobic 
valine (HBBglu6val) to create sickle hemoglobin (HbS). Deoxygenation of HbS leads to the 
polymerization of hemoglobin fibrils that alter red blood cell (RBC) morphology into the 
characteristic sickle shape (Barabino et al., 2010). Sickling of RBCs is a temporarily reversible 
process; however, each oxygenation and deoxygenation cycle stiffens the RBC membrane, 
reducing the deformability necessary to pass through capillaries and altering blood rheology. These 
events of sickling and abnormal blood flow contribute to the pathological hallmarks of SCD: vaso-
occlusion and hemolysis (Figure 2.1).  
 
  





Vaso-occlusive crisis occurs when sickle RBCs obstruct blood flow, causing pain and 
ischemic injury to the supplied tissue. Pain attributed to vaso-occlusion is one of the most common 
reasons for hospitalization for sickle patients (Almeida and Roberts, 2005). The RBC membrane 
damage caused by HbS polymerization leads to the presentation of transmembrane proteins on the 
cell surface increasing RBC adhesiveness (Barabino et al., 2010; Hebbel, 2008; Figure 2.2). The 
presence of adhesion molecules on the surface has been associated with sickle RBC interaction 
with capillary endothelium via VCAM-1, ICAM-1, P-selectin, E-selectin, and subendothelial 
matrix proteins (i.e. laminin and von Willebrand factor) (Gutsaeva et al., 2011; Kaul et al., 2009; 
Turhan et al., 2002). Frenette and colleagues suggest that activated leukocytes rolling along the 
vessel wall interact with surrounding sickle RBCs and platelets to occlude post-capillary venules 
(Manwani and Frenette, 2013). Crises can be initiated by additional factors including 
inflammation, increased blood viscosity, and hemolysis; collectively, the sickle RBC 






Although RBC sickling is a reversible process, the repeated sickling and unsickling cycle 
“ages” the cell and leads to premature hemolysis. On average, sickle RBCs have a lifespan one-
sixth of their native counterparts, resulting in an increased proportion of immature RBCs called 
reticulocytes (Franco, 2012). Within these young cells are higher concentrations of arginase, 
hemoglobin, hemin, and iron, all of which can be released into the plasma during hemolysis (Kato 
et al., 2017; Morris, 2005). The intensity of hemolysis varies in patients, but nearly all sickle 
patients have an excessive amount of cell-free hemoglobin and a significantly decreased 
concentration of the hemoglobin and heme scavengers haptoglobin and hemopexin, respectively 
(Kato et al., 2017). Translocation of RBC contents to the intercellular space between the vascular 
Figure 2.2 - Sickle cell altered membrane properties. Reprinted from Frenette & Atweh, 




endothelium and smooth muscle cells leads to pathologic iron accumulation within tissues (Tsay 
et al., 2010). Subsequent iron storage depletes local antioxidant availability and generates reactive 
oxygen species (Schafer et al., 2013). 
Oxidative Stress Background  
Reactive oxygen species (ROS) refers to the intermediary molecules such as superoxide, 
hydrogen peroxide, and hydroxyl free radicals derived from the metabolism of oxygen (Dröge, 
2002; Tu and Weissman, 2004). These metabolites are products of intracellular processes within 
organelles (i.e. mitochondria) or independent enzyme systems that require oxygen as an electron 
acceptor such as transmembrane oxidases. ROS also can be further reduced into other forms of 
ROS (Figure 2.3). For example, dismutase superoxide converts into hydrogen peroxide, which can 
be further transformed into the highly reactive hydroxyl radicals via iron-catalyzed Fenton and 
Haber-Weiss reactions (Fenton, 1894; Harber and Weiss, 1934). ROS generation in healthy 
individuals is counterbalanced by the production of antioxidants that neutralize ROS molecules 
thereby preventing or limiting oxidative damage. Antioxidants can be categorized into either 
enzymatic (superoxide dismutase (SOD), catalase, glutathione peroxidase (GPX), and nitric oxide 
(NO)) or non-enzymatic (tocopherols, reduced glutathione (GSH), carotenoids, ascorbic acid, 
lipoic acid, ubiquinols, selenium, riboflavin, zinc, carotenoids, uric acid and metal-binding 
proteins) (Birben et al., 2012). If the antioxidant capacity is exceeded, remaining ROS can target 
nearby cells causing dysfunction or death. The resulting imbalance of ROS and antioxidants in 





Oxidative stress is a key contributor to the pathological mechanisms of SCD (Chirico and 
Pialoux, 2012). Within the RBC, HbS autoxidizes into methemoglobin and produces superoxide 
nearly twice as fast as normal hemoglobin (Hebbel, 1985). Once released into the plasma, 
methemoglobin is broken down further by hydrogen peroxide to release catalytic iron molecules 
that propagate hydroxyl formation (Rifkind et al., 2014). Excessive hemolysis further increases 
ROS generation due to sequestration of the antioxidant nitric oxide (Morris, 2005; Schaer et al., 
2013). The recurrence of ischemia-reperfusion injury increases endothelial expression of several 
oxidases such as NADPH oxidase and endothelial xanthine oxidase (Yuan et al., 2004). 
Furthermore, ROS activity resulting from sickle RBC interactions with vascular endothelium 
upregulates the expression of NF-kB transcribed adhesion molecules, continuing the vicious 
ischemia-reperfusion cycle (Sultana et al., 1998). Lastly, the chronic proinflammatory state of 
SCD may be directly related to oxidative stress. ROS are known inducers of inflammatory cytokine 
expression to fend off foreign body pathogens and facilitate injury repair. However, sickle patients 




have an elevated number of activated leukocytes that produce large amounts of ROS at sites of 
inflammation and injury (Dahlgren and Karlsson, 1999; Lard et al., 1999; Wun, 2001).  
SCD further promotes oxidative stress by having an insufficient antioxidant population. 
Initial response to cell-free hemoglobin derived ROS comes from endothelial secretion of HO-1, 
which converts heme into carbon monoxide and biliverdin (a bilirubin precursor) as well as 
releasing labile iron that later binds ferritin (Belcher et al., 2010). Ferriaira and colleagues suggest 
that carbon monoxide and biliverdin created from heme conversion may serve as non-enzymatic 
antioxidant that protects cells from oxidative stress in addition to ferritin (Queiroz and Lima, 
2013). This concept is supported by HO-1 overexpression in sickle patients and transgenic mice, 
while other major enzymatic antioxidants such as superoxide dismutase and catalase are deficient 
due to downregulation of nuclear factor erythroid 2–related factor 2 (Nrf2) activity (Keleku-
Lukwete et al., 2015). Nrf2 is an essential transcription factor responsible for the expression of the 
aforementioned antioxidants and various other cytoprotective molecules against oxidative stress 
independent of the HO-1 pathway (Nguyen et al., 2009). Induced expression of Nrf2 in sickle mice 
reduces the number liver and lung necrotic areas as well as improves inflammation and heme 
elimination (Keleku-Lukwete et al., 2015). In regards non-enzymatic antioxidants, numerous 
reports have demonstrated that sickle patients have lower levels of carotenoids, flavonoids, zinc, 
vitamins C and E; however, supplementation has yet to serve as a viable therapeutic option 
(Kiefmann et al., 2008; Muskiet et al., 1991). Altogether, the assorted sources of ROS and lack of 
sufficient antioxidant defenses promote chronic oxidative stress that affects nearly every organ 




The result of the complex vasculopathy of SCD is major organ failure (Figure 2.4). 
Asymptomatic vascular damage begins years before clinical symptoms manifest at which point 
the damage is irreversible and progresses throughout life. Autosplenectomy tends to be the first 
clinically apparent indication of organ failure in sickle patients (Powars, 1990). Intracranial 
hemorrhaging, acute strokes and resulting atrophy can occur in both children and adults with SCD 
(Ballas et al., 2012). In addition to chronic pain, there are numerous cases of sickle patients with 
hepatobiliary disease (cirrhosis, cholestasis, jaundice, and hepatic sequestration), end-stage renal 
failure (glomerulosclerosis), chronic lung disease (acute chest syndrome and pulmonary 
hypertension), retinopathy, crippling leg ulcers, and heart failure (Shah et al., 2017; Powars, 1990). 
Some therapeutic interventions for SCD can potentially damage organs such as routine blood 
transfusions leading to liver infection from hepatitis B and C as well as iron overload (Banerjee et 
al., 2001). Although the histopathology of SCD encompasses several organ systems, sickle bone 
is significantly under-investigated.  
 




The majority of chronic pain reported by sickle patients is localized to the bone and joint 
regions. The femoral head, humeral head, and vertebral bodies are frequent sites of bone 
destruction due to avascular necrosis. However, septic osteomyelitis and marrow infarcts are 
relatively common occurrences in sickle patients as well. Phenotypically sickle adult bone closely 
resembles osteoporotic bone with a widening of the marrow cavity and reduced bone mass. 
Normally hematopoietic red marrow is converted to yellow marrow within the long bones over 
time to support osteogenesis and long-term hematopoietic stem cell activity (Gimble et al., 1996). 
However, sickle patients experience erythropoietic hyperplasia to compensate for the reduced 
lifespan of sickle RBC, thereby maintaining and expanding red marrow (Madani et al., 2007). 
Unfortunately, marrow infarcts occur more frequently in red marrow than yellow and are generally 
considered clinically silent until discovered incidentally by conventional radiological scans (Lal 
et al., 2006; Milner et al., 1991; Rao et al., 1989; Sarrai et al., 2007). The resulting femoral hip 
fractures and collapse of vertebral bodies in sickle patients are largely attributed to the existing 
paradigm of occlusion/ischemia derived osteonecrosis. However, an increasing body of knowledge 
about the role bone plays in overall health garners a deeper understanding of the relationship 
between SCD and bone. 
2.2. Bone Background 
Bone is a highly adaptive tissue characterized by its ability to facilitate body movement 
and protect vital organ systems. Its mineralized extracellular matrix serves as a reservoir for growth 
factors, cytokines, and calcium/phosphate homeostasis. Bone also houses various stem cells within 
the red and yellow marrow to replace and repair damaged tissues. Bone can be organized into two 
types: cortical and cancellous (Figure 2.5). Cortical bone is the highly packed and dense outer 
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layer of bone tissue that surrounds the marrow cavity (Thomas, 2007). Cancellous, or trabecular, 
bone is an organized network of rods and plates that allows the distribution load to the stiffer 
cortical bone (Thomas, 2007). The functional units of both cortical and cancellous bone are known 
as osteons, cylindrical structures of concentric lamellae. Bone nourishment and enervation exist 
within the periosteum and endosteum, which cover the outer and inner parts of the bone 
respectively. At the center of each osteon is the Haversian canal, a channel dedicated to housing 
blood vessels that anastomosis with the main vasculature of the endosteum.  
 
 
Figure 2.5 – Basic structure and anatomy of bone tissue. Image adapted with permission 





Bone Composition: Osteoclasts 
Bone tissue is composed of and maintained by four cell types: osteoclasts, osteoblasts, bone 
lining cells, and osteocytes (Figure 2.6). Osteoclasts are multinuclear bone resorbing units derived 
from monocyte/macrophage lineage cells. Osteoclastogenesis is stimulated by 
monocytes/macrophage-colony stimulating factor (M-CSF) and the receptor activator of nuclear 
factor kappa B ligand (RANKL). Once formed, osteoclasts adhere to the bone surface and create 
a tight seal via αvβ3 integrin to concentrate the release of mineral and matrix degrading protons 
and proteases including cathepsin K (Atley et al., 2000; Linsuwanont et al., 2002; Niikura et al., 
2005). During mineral deficiencies, calcium and phosphate ions move through the osteoclasts and 
release into the extracellular fluid space (Salo et al., 1997). Osteoclasts are temporarily formed and 
undergo apoptosis once bone resorption is completed. Previous studies have demonstrated that 
biomarkers of osteoclast formation and activity (RANKL, IL-6, tartrate-resistant acid phosphatase 
Figure 2.6 – The different types of cells found within bone tissues. Image 
adapted with permission from OpenStax Biology.  
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type 5b) are upregulated as much as three times more in sickle bone than wild-type controls (Dalle 
Carbonare et al., 2015; Nouraie et al., 2011).  
Bone Composition: Osteoblasts 
Osteoblasts are responsible for the deposition of bone extracellular matrix (ECM) and 
hydroxyapatite mineralization. Bone matrix is largely composed of collagen type I but also 
features osteonectin, osteopontin, and bone sialoprotein (Manolagas, 2000; Sommerfeldt et al., 
2001). Osteoblast progenitor cells, mesenchymal stem cells, reside in the marrow cavity, 
periosteum, and endosteum prepared to replace damaged bone (Knight and Hankenson, 2013). 
During the formation process, approximately 15% of osteoblasts are entombed in the bone ECM 
and mature into osteocytes (Franz-Odendaal et al., 2006). The remaining osteoblasts are either 
transformed into bone-lining cells or undergo apoptosis. Bone-lining cells are flattened dormant 
cells found on the bone surface. Although the function of bone-lining cells is relatively unknown, 
studies suggest that disruption of the lining may incite remodeling as well as form the cell canopy 
of the remodeling complex (Hauge et al., 2001).   
Bone Composition: Osteocytes 
Comprising more than 90% of the cell population in bone, osteocytes are regarded as the 
master orchestrators of bone via mechanotransduction and regulation of osteoclast and osteoblast 
activity (Bonewald, 2011; Schaffler et al., 2014). As stated above, osteoblasts mature into 
osteocytes after being trapped in the newly mineralized matrix. Osteocytes lose the ability to 
produce osteoblast proteins largely associated with bone ECM such as collagen type I and alkaline 
phosphatase. However, osteocytes notably produce proteins that are predominantly found in bone 
tissue including: E11, dentin matrix acidic phosphoprotein 1 (DMP1), matrix extracellular 
phosphoglycoprotein (MEPE), fibroblast growth factor 23 (FGF23), and sclerostin (Dallas et al. 
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2013). These proteins represent an array of functions ranging from the regulation of mineralization 
(DMP1, sclerostin) to phosphate homeostasis (MEPE, FGF23) and cytoskeletal renovation 
enabling dendrite formation (E11) (Dallas et al., 2013). 
Osteocytes have a stellate morphology with several dendritic processes connecting 
osteocytes to each other as well as surface lining cells, osteoblasts, and the vasculature. The 
osteocyte body and processes are housed within the lacunae and canaliculi respectively, which 
form the lacunar-canalicular system (LCS). Interstitial fluid movement within the LCS allows 
osteocyte exchange of oxygen, nutrients, signaling molecules, and waste (Bonewald and Prideaux, 
2012). Shear stress experienced by osteocyte processes during load serves as the 
mechanotransduction mechanism (Burra et al., 2010). Gap junctions between osteocytic processes 
allow for the direct communication between neighboring cells and transfer of signaling molecules 
to cells located further from the initiating osteocyte (Yellowley et al., 2000). Load activated 
osteocytes upregulate Wnt/catenin signaling pathway in osteoblasts and stimulates bone formation 
(Poole et al., 2005). The lack of shear stress signaling commonly experienced with disuse 
decreases osteocyte activity and induces apoptosis derived bone resorption (Cabahug-Zuckerman 
et al., 2016). 
Osteocytes are also capable of functioning as both effector and endocrine cells for the 
regulation of mineral homeostasis as well as bone remodeling via osteoblast and osteoclast 
coordination (Dallas et al., 2013). Osteocytes secrete inhibitory compounds FGF23 and sclerostin 
into the extracellular space to prevent kidney reabsorption of phosphate and osteoblast 
mineralization respectively. Additionally, osteocytes are primary producers of osteoclast forming 
RANKL and its antagonist osteoprotegerin (OPG).  
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Several systemic signaling molecules including parathyroid hormone (PTH), estrogen, 
calcitonin, and glucocorticoids are known to regulate osteocyte activity. For example, clinically 
prescribed low dosage PTH is regarded as an anabolic therapy to retain bone mass (Saidak et al., 
2014). Whereas high and chronic PTH exposure inhibits osteoblast activity via sclerostin and 
induce RANKL osteoclastogenesis (Kroll, 2000). PTH also contributes to phosphate regulation by 
inducing osteocyte FGF23 expression (Bergwitz and Jüppner, 2010). However, the concentration 
of signaling molecules such as PTH varies amongst sickle patients and their influence on sickle 
bone remains relatively unknown. 
2.3. Oxidative Stress Uncouples Bone Remodeling 
One of the key functions of osteocytes is to utilize the information from extrinsic factors 
(i.e. load, growth factors, oxygen, hormones, etc.) to initiate and regulate bone remodeling to 
maintain skeletal integrity. Unlike modeling that adapts bone structure to demands placed upon it, 
bone remodeling is a reparative process that requires balance between osteoblast formation and 
osteoclast resorption.  The disruption of this balance may lead to unchecked mineralization 
(osteopetrosis) or excessive resorption (osteopenia and osteoporosis). Like most tissues, ROS are 
essential for normal bone physiology. Osteoclast differentiation is dependent on endogenous 
superoxide and hydrogen peroxide regulation of NF-kB activity (Lee et al. 2005). Furthermore, 
intracellular ROS stimulates RANKL expression in bone marrow stromal cells and osteoblasts 
(Wauquier et al. 2009).  ROS have also been shown to induce osteoblasts apoptosis in vitro 
(Almeida et al. 2007). Prolonged oxidative stress reduces osteoblast mineralization, inhibit  
maturation, and expression of OPG which favors osteoclastogenesis (Wauquier et al. 2009). 
Oxidative stress caused by natural aging, disuse (Cabahug-Zuckerman et al., 2016), 
microdamage (Verborgt et al., 2000), estrogen deficiency (Emerton et al., 2010), glucocorticoid 
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excess (Canalis and Delany, 2002) triggers osteocyte apoptosis induced bone remodeling. 
Inhibition of osteocyte apoptosis has proven effective at preventing bone resorption but is not a 
suitable clinical therapy due to the risk of promoting cancer development (Cardoso et al., 2009). 
Moreover, dying osteocytes signal to neighboring viable osteocyte to begin the remodeling as well 
as promote anti-apoptotic gene expression to prevent the spread of apoptotic signaling (Kennedy 
et al., 2012; Verborgt et al., 2002).  
Recent studies suggest that osteocytes undergo senescence and play a key role in age-
related bone degeneration (Farr et al., 2016). In general, senescence is a cellular response that 
prevents the proliferation of dysfunctional cells because of DNA and mitochondrial oxidative 
damage accumulated over time (Ziegler et al., 2015). In turn, senescent cells are highly resistant 
to apoptosis, remain metabolically active, and secrete combinations of proinflammatory cytokine, 
chemokine, and ECM proteins that create a noxious microenvironment known as senescence-
associated secretory phenotype (Coppé et al., 2008). Senescence can also be induced prematurely 
by various signals including oxidative stress and other senescent cells (Marie, 2014; Nelson et al., 
2012; Pole et al. 2016). With respect to bone, osteocyte senescence has been associated with 
decreased bone formation and stimulation of pro-resorptive signaling from neighboring cells in 
the marrow (Farr et al., 2016; Marie, 2014). The use of senescent cell ablation animal models 
suggests that removal of these cells delays the onset of age-related manifestations in soft tissues 
(Baker et al., 2011) and may preserve skeletal structure (Zhu et al., 2015). 
Non-Transfusional Iron Overload in SCD   
Homeostatic metabolism of iron depends on bioavailability of the circulating protein, 
transferrin, to safely transport iron to the liver and bone marrow for erythropoiesis. Iron overload 
is typically considered a negative aspect of frequent blood transfusions for patients with SCD, due 
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to the saturation of serum transferrin and absorption of highly reactive non-transferrin bound iron 
molecules into cells (Wang et al. 1986; Esposito et al. 2003). In general iron overload studies in 
SCD are transfusion focused and compared to 𝛽-thalassemia outcomes, to which SCD patients do 
not manifest the severe cardiomyopathies or endocrinopathies seen in 𝛽-thalassemia (Wood et al. 
2004, Vichinsky et al. 2005, Walter et al. 2006). However, non-transfused SCD patients have 
relatively little transferrin saturation but have similar serum and hepatic iron content to transfused 
SCD and 𝛽-thalassemia patients (Hedo et al. 1993; Vichinsky et al. 2005, Yassin et al. 2017). Non-
transfusional iron overload occurs in conditions of chronic RBC destruction and hemolysis, most 
notably 𝛽-thalassemia, but little is known as to whether this may occur in SCD. Walter and 
colleagues suggest that iron metabolism and trafficking differ in SCD than that of other 
hemoglobinopathies, in that the chronic inflammation of SCD may upregulate retention of iron 
within renal tissue and reticuloendothelial system, specifically the spleen and liver (2009). 
Inflammatory cytokines interleukin (IL)-6 and IL-1𝛽, which are chronically elevated in SCD, have 
been shown to prevent the release of RBC derived iron from splenic and hepatic macrophages 
(Knutson et al. 2005). Subsequently, this leads to an iron deficiency or complete absence in the 
bone marrow disrupting erythropoiesis, which is commonly seen in patients with SCD during 
adolescence and adulthood (Oluboyede et al. 1981; Rao et al. 1983).  
Outside of SCD, iron retention within tissue is associated with oxidative stress and 
disruption of normal physiology. Hepatic accumulation of excessive iron in particular leads to 
dysfunctional iron homeostasis in favor of resorption and diminished synthesis of molecules and 
proteins vital for bone development, namely vitamin D and insulin like growth factor-1 (Chow et 
al. 1985; Kowdley 2016; De Sanctis et al. 2015, Runchey et al. 2014). In addition to soft tissues, 
supranormal concentrations of iron is believed to interfere with bone formation and remodeling. 
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Osteoporosis and fractures are frequently associated with iron overload in conditions such as 𝛽-
thalassemia (Vogiatzi et al. 2006). Animal models show that non-transferrin bound iron can 
accumulate within the bone tissue inducing oxidative stress, inflammation, and bone resorption 
(Tsay et al. 2010). When cultured, exogenous iron accelerates RANKL induced osteoclastogenesis 
and activity (Wang et al. 2018). Additionally, increased serum levels of iron may directly inhibit 
osteoblast mineralization (Zarjou et al. 2010). The majority of these studies also report that the 
administration of exogenous antioxidants, such as N-acetylcysteine, prevents bone loss thereby 
highlighting iron overload derived oxidative stress bone loss.  
2.4. Antioxidant Therapy for Bone Loss 
The development and utilization of antioxidant-based strategies targeted to bone loss is of 
major interest to the field. Reductions in the concentrations of plasma antioxidants are correlated 
with age and post-menopausal osteoporosis (Domazetovic et al. 2017). Antioxidants appear to play 
a role in bone homeostasis and remodeling by preventing osteocyte apoptosis, reducing 
osteoclastogenesis, and promoting osteoblast differentiation and mineralization (Fontani et al. 
2015; Romagnoli et al. 2014; Banfi et al. 2008). This benefit has been mechanistically attributed 
to the maintenance of cellular concentrations of the key antioxidant glutathione (GSH) by 
scavenging excess ROS  (Romagnoli et al. 2013; Franco et al. 2007). The aforementioned 
antioxidant therapy, N-acetylcysteine, prevents bone loss during iron overload and estrogen loss 
(ovariectomy) by serving as a substrate precursor to replenishes GSH levels (Atkuri et al. 2007; 
Polat et al. 2017). However, the body’s ability to synthesize GSH declines with age and certain 
conditions, especially liver disease (Schmitt et al. 2015).  
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Glutamine Therapy for SCD 
Recently, the Food and Drug Administration (FDA) approved of L-glutamine (GLN) under 
the premise of reducing the acute complications of SCD by increasing antioxidant capacity of RBC 
(Niihara et al. 2018). Opposing research has led to uncertainty about the proposed therapeutic 
mechanism and its long-term safety (Quinn 2018). GLN is utilized ubiquitously as a precursor for 
the synthesis of GSH, nucleic acids, and other amino acids; therefore, the benefit experienced by 
sickle patients may be explained by other means outside of RBC usage. Under normal conditions 
the liver is one of the primary sources of GLN for the body. During disease states, the liver 
becomes a major site of GLN consumption to maintain homeostatic activity (ie. urea 
cycle/nitrogen metabolism) and reduce hepatic damage from oxidative stress (Cruzat et al. 2018). 
However, there is precedence of increased mortality with GLN therapy in populations at risk of 
renal insufficiency, hepatic dysfunction, and multi-organ failure; which are all associated with 
SCD (Quinn 2018). Additional studies are needed to better understand the relationship between 

















CHAPTER 3: MICROARCHITECTURE AND BIOMECHANICS OF SICKLE BONE† 
3.1. Introduction 
The etiology of SCD pain has been classically regarded as acute vaso-occlusive episodes 
by hematologists (Sharma and Brandow 2019). Today the pathophysiology of sickle pain is 
understood to be multifaceted, with contributions from vascular occlusion, ischemia-reperfusion 
injury, oxidative stress, chronic inflammation, and neuropathic pain (Tran et al. 2017; Brandow et 
al. 2017; Smith et al. 2008; Sharma and Brandow 2019). Patients with SCD often report chronic 
pain in multiple body locations, with bone regions (ie. knee, hip, and shin) being the most 
frequently self-reported (McClish et al. 2009). However, the true prevalence of a sickle bone 
pathology has been difficult to determine due to the lack of clinical prospective studies, 
standardized diagnostic procedure, and the development of routine care and technologies for SCD 
that is seen in other disorders such as cystic fibrosis (Ware et al, 1991; Adekile et al, 2001; Gupta 
& Adekile, 2004). 
Phenotypically, sickle bone can resemble osteoporosis, from which it became the norm to 
utilize bone mineral density (BMD) levels obtained from dual-energy X-ray absorptiometry 
(DXA) to clinically monitor bone health and predict fracture risk (Brinker et al., 1998; World 
Health Organization, 1994). However, the unreliable interpretations of DXA results have led to 
numerous misdiagnoses due to overestimating and underestimating BMD levels in general (Gafni 
and Baron, 2004; Wren et al., 2005). Additionally, variations in the BMD of sickle patients are 
based on age, gender, and ethnicity, further minimizing the usefulness of BMD to monitor sickle 
bone by itself (Almedia and Roberts, 2005; Gupta et al., 2009; Lal et al., 2006; Sarrai et al., 2007). 
†Adapted and modified from Green M, Akinsami I, Lin A, Banton S, Ghosh S, Chen B, Platt M, 
Osunkwo I, Ofori-Acquah S, Guldberg, R, and Barabino G. (2015) Microarchitectural and 




The utilization of microcomputed tomography (microCT) provides a platform for the 
fabrication of high-resolution 3D images of the bone microenvironment in a non-destructive and 
time-lapsed fashion, furthering the ability to quantitatively assess bone quality (Bouxsein et al., 
2010). Unlike DXA, microCT determines the tissue mineral density (TMD) of the mineralized 
bone tissue only, which directly influences clinical BMD measurements but negates the attenuation 
of soft tissue (muscle, bone marrow, etc.) that may complicate interpretations. Currently, high 
resolution clinical microCT technology is limited only to the extremity regions of the body; 
however, the use of animal models with microCT serves as a critical tool for investigating human 
pathology (Wang et al., 2005). In lieu of such technological advancements and established 
knowledge, the bone phenotype in SCD has yet to be characterized beyond monochromatic x-rays. 
To our knowledge, this body of work serves as the first peer-reviewed investigation into the 
pathology of SCD bone using microCT, thereby filling that gap in knowledge. 
Furthermore, the unique microarchitecture of the trabecular regions influences whole bone 
strength, yielding various mechanical properties dependent on quality and organization of the bone 
(Gibson, 1985; Turner et al., 1990; Ulrich et al., 1997). Albeit an under investigated aspect of 
SCD, nearly 30% of adult sickle patients self-reported multiple fractures due to low impact trauma 
in various locations, including the vertebrae, wrist, metatarsal, and femoral bones (Arlet et al. 
2013). Multiple fractures have also been reported in children with sickle cell disease as young as 
19 months (Omer et al., 2013) and may continue to occur throughout adolescence, sometimes 
accompanied with osteomyelitis (Ebong, 1986). To further examine the effects of SCD in bone, 
we performed biomechanical testing to determine the material properties of homozygous sickle 
mouse bone with respect to sickle cell trait carriers, wild-type controls and age. 
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3.2 Materials and Methods 
3.2.1 Experimental Animals 
In order to characterize the sickle bone phenotype, we employed a Townes transgenic 
sickle mouse model and C57BL/6 wild-type controls (Ghosh et al., 2012; Ryan et al., 1997). Mice 
were selectively mated and categorized into either homozygous (SS) or heterozygous (AS) 
expression as determined by PCR. Analysis using microCT and biomechanical testing was 
conducted on femurs that were harvested without chemical fixation from 10- and 21-week-old 
male mice and stored frozen at -20°C wrapped in phosphate buffer saline-soaked gauze until time 
of analysis (n = 3-6/group). All protocols were IACUC approved by Emory University and the 
Georgia Institute of Technology. 
3.2.2 Microcomputed Tomography 
The trabecular and cortical bone morphologies of femurs were examined by microCT 
imaging (μCT 40, Scanco Medical, SUI), as previously reported (Robertson et al., 2006). 
Morphological and mineral density analyses were conducted on the femoral, cortical, and 
trabecular regions scanned at a voxel size of 12 μm (Figure 3.1, shaded areas). Two regions of the 
distal femur were evaluated – one region in the epiphysis (0.32 mm in length distal of the growth 
plate) and one region in the metaphysis (extended 0.80 mm towards the diaphysis from an initial 
point 0.05 mm proximal to the growth plate). Within these regions, trabecular and cortical bone 
were first spatially segmented using an auto-contouring program, then each volume was manually 
checked and adjusted to ensure consistent boundary properties. For the diaphyseal region, cortical 
bone geometry and morphology were evaluated in a 1.0 mm mid-diaphyseal scan, which 
corresponded with the area tested in four-point bending (Figure 3.1) (Buie et al., 2007). Distinction 
between mineralized and soft tissue within the metaphyseal, epiphyseal, and diaphyseal regions 
 
26 
was maintained by global thresholds of 155, 162, and 205, with representative hydroxyapatite 




3.2.3. Analysis of bone morphology and microarchitecture 
Morphometric analyses of trabecular and cortical bone followed previously established 
direct distance transformation algorithms within the Scanco evaluation software (Hildebrand and 
Rüegsegger, 1997; Robertson et al., 2006). We reported trabecular spacing (Tb.Sp), trabecular 
thickness (Tb.Th), trabecular number (Tb.N), trabecular connectivity density (Conn.D), bone 
volume (BV), total volume (TV), bone volume fraction (BV/TV), and structure model index 
(SMI), as well as the cortical bone area (Ct.Ar), total area (Tt.Ar), cortical bone area fraction 
(Ct.Ar/Tt.Ar), cortical thickness (Ct.Th.), and moment of inertia around the medial lateral axis 
(IML). 
Figure 3.1 - Schematic setup of interest point bending and femur placement. The regions 
of four that were scanned and analyzed by micro- and analyzed by micro CT for 
morphological assessment are a black highlighted. Location of the growth plate between 
trabecular regions is represented as a line. The distance between the two upper points is 




3.2.4. Analysis of tissue mineral density 
Bone tissue mineral density was determined from the regions scanned by microCT. A 
series of hydroxyapatite (HA) phantoms with known densities were used to calibrate the system. 
MicroCT data were converted into true mineral density values (mg HA/cm3) from a standard linear 
attenuation curve. Average mineral density values across all thresholded bone voxels in the 
specified volume of interest were reported. 
3.2.5. Mechanical testing via four-point bending 
Femoral mechanical properties were measured via four-point bending with a MTS 858 
Mini Bionix (Eden Prairie, MN) mechanical testing system as previously reported (Robertson et 
al., 2007). Briefly, thawed femurs were placed on support pins spaced 6.2 mm wide with radius of 
curvature 0.5 mm while a load was applied at a rate of 0.05 mm/s until failure (Figure 3.1). Femurs 
were tested in the anterior-posterior plane where the upper pins were centered on the posterior side 
of the mid-diaphyseal location scanned by microCT. The force and deflection data obtained from 
the MTS system were used to calculate stiffness, yield force, post yield deflection (PYD), and 
work to failure. The yield point was defined with a 10% reduction of secant slope from the linear 
region of the force-deflection curve. The force-deflection data were normalized using the moment 
of inertia data obtained from the microCT analyses to calculate stress (σ) and elastic modulus (E) 
with equations (1) and (2), respectively; where F = applied force, c = 1/2 of anterior–posterior axis, 
a = horizontal distance between upper and lower supports (2 mm), IML = 2nd moment of area 
about the medial–lateral axis, S = stiffness, L = horizontal distance between upper and lower 
supports (6.2 mm). 
σ = F(ac ∕ 2IML) (1) 
E = S(a2 ∕ 12IML)(3L − 4a) (2) 
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3.2.6. Statistical analysis 
Data were analyzed by analysis of variance (ANOVA) tests with post-hoc t-test for 
pairwise comparison either between genotypes or age. All data are represented as mean ± standard 
error of the mean (SEM). A p-value < 0.05 was considered statistically significant. 
3.3 Results 
3.3.1. Bone Tissue Mineral Density 
Femoral cortical and trabecular TMD were measured with microCT. TMD did not differ 
significantly between AA, AS, or SS at either 10 or 21 weeks of age, as determined by ANOVA 
(Table 3.1). Overall, at 21 weeks TMD was as much as 10% higher for some regions of analysis 
at 10 weeks among the three groups. However, the metaphysis in SS bone did not have as much 
of an increase in TMD when compared to AA and AS. 
 
Table 3.1 - Femoral bone mineral density levels in 10- and 21-week old sickle cell (SS) 





3.3.2. Mid-Diaphyseal Cortical Geometry 
At the mid-diaphysis, the total area did not differ between the three groups at 10 weeks of 
age; however, AA femurs exhibited significantly larger areas of mineralized tissue compared to 
AS and SS femurs (p<0.05) (Table 3.2). Although the total area increased with age among the 
genotypes, the amount of mineralized tissue present was reduced as much as 27% in the AS and 
SS femurs than in the AA mouse (p<0.05). Moreover, SS femurs exhibited a significantly lower 
areal fraction of cortical bone compared to AA and AS at 10- and 21-weeks due to maintenance 
of a relatively smaller area of mineralized bone while displaying as much as a 10% increase in 
total area with maturation (p<0.05) (Figure 3.2A). At 10 and 21 weeks, average cortical thickness 
was significantly thinner in SS bone than the AA control and AS (p<0.05). Qualitative differences 
were noticed in endosteal and periosteal shape at the mid-diaphysis, with SS femurs displaying 





Figure 3.2 - Micro-CT measured area and volume occupied by mineralized tissue within 
cortical (mid-diaphyseal) and trabecular (metaphyseal and epiphyseal) bone respectively 
at the ages of 10 and 21 weeks. Data shown represent mean ± SEM. * indicates 






Figure 3.3 -MicroCT generated representative 3D heat maps of AA, AS, and SS 
femoral mid diaphyseal cortical thickness of at 21 weeks of age. Thickness is 
depicted in pseudocolor scale, red (0.2 mm) to blue (0 mm). Scale bar equals 
200 μm. 
 





3.3.3. Trabecular Bone Microarchitecture 
Within the trabecular metaphyseal and epiphyseal regions, there were no differences in 
BV/TV amongst the genotypes for younger animals (Figure 3.2B & 3.2C). Older animals exhibited 
a universal reduction in the percentage of total volume occupied by mineralized tissue in all 
specimens except the AA epiphyseal region (p<0.05). In comparison to AA and AS, SS bone 
occupied significantly less bone volume in the trabecular regions (p<0.05). 
Trabecular number, thickness, spacing, connectivity density, and SMI were characterized 
within the distal femoral epiphysis and metaphysis of AA, AS, and SS mice at 10 and 21 weeks of 
age (Table 3.3). Qualitative observations from microCT images of trabecular regions suggested 
thinner trabeculae for SS (for both regions and both ages) as well as greater trabecular spacing in 
the metaphysis of AS and SS mice at 21 weeks (Figure 3.4). Quantitative analyses of Tb.Th. 
confirmed significant difference for SS compared to AA in the epiphysis but not metaphysis at 21 
weeks of age (p<0.05). Significant increases measured for Tb.Sp. in the metaphysis with 
maturation agreed with previous observations of SS bones having greater trabecular spacing (Table 
3.3). Additionally, microCT analyses revealed that specifically within the metaphyseal region, AS 
and SS femurs exhibited significantly lower Tb.N. than AA controls at 21 weeks of age (p<0.05). 
At 10 weeks, the difference in interconnectivity of the trabecular regions of the different genotypes 
was negligible (Table 3.3, Figure 3.5). At 21 weeks epiphyseal connectivity density showed a 
universal reduction with respect to age but no significant difference across genotypes, while a 
reduction of up to 80% was observed in SS and AS metaphyseal connectivity density compared to 
the AA control (p<0.05) (Table 3.3, Figure 3.5B). SS femurs also exhibited significant 
deterioration of connectivity density among individual genotypes with respect to age, in which 
epiphyseal and metaphyseal regions were reduced by 30% and 90% respectively (p<0.05). 
Trabecular SMI was also measured, in which the geometry of trabeculae was characterized as 
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either “plate-like” or “rod-like,” represented within a scale of 0 to 3, respectively. All genotypes 
underwent a progression toward more rod-like trabeculae with age (Table 3.3). Notably, SS 
trabeculae showed a significantly larger transition toward a higher SMI than AA and AS controls 
in the metaphyseal region (p<0.05). 
 
 
Figure 3.4 - Micro-CT generated representative 3D map of epiphyseal (top) and 
metaphyseal (bottom) trabecular morphology with respect to genotype and age. 







Figure 3.5 - Epiphyseal and metaphyseal trabecular connectivity densities determined by 
micro- CT scans in AA, AS, and SS from 10- and 21-week old mice femurs. Data shown 











3.3.4. Biomechanical Properties 
Femurs were evaluated via four-point bending to determine the mechanical properties 
relative to genotype and age (Table 3.4, Figure 3.6). At 10 weeks, maximum force, yield force, 
work to failure, ultimate stress, and yield stress were comparable across genotypes. At 21 weeks, 
AA and AS displayed similar thresholds for yield and maximum forces and stresses, while, SS 
bones could only withstand approximately 40% less force and stress than AA and AS (p<0.05). 
Additionally, SS femurs deformed with a significantly lower yielding force at 21 weeks than at 10 
weeks in comparison to the other genotypes that required relatively similar forces (p< 0.05). The 
PYD for AS and SS bone at 10 weeks-of-age were significantly larger than the AA control; 
however, the PYD between genotypes did not differ with maturation (p<0.05). The work required 
for the femurs to fail, which is associated with PYD, remained relatively similar among genotypes 
at both ages. SS femora were significantly less stiff and demonstrated a lower elastic modulus than 
AA and AS at 10 and 21 weeks-of-age (p<0.05). Furthermore, the femoral elastic modulus tended 
to decrease with maturation for AA and SS specimens; however, the 21-week-old AS femora had 






Figure 3.6 - Force-displacement curves representative of the mechanical behavior of 







The pathology of SCD disturbs the metabolic activity and damages the structural integrity of 
tissues throughout the body, resulting in sporadic and acute pain most commonly affecting bone 
and joints (Aguilar et al., 2005). Through conventional radiology, it is widely accepted that SCD 
in bone results in widening of the bone marrow cavity, along with a decrease in bone thickness 
and mineral content; however, the morphology of sickle bone at the microscale and its 
Table 3.4 - Femoral mechanical properties generated by four point bending in 10- and 




contribution mechanically is still largely uncharacterized (Almeida and Roberts, 2005). In order 
to gain further insight into how SCD and age affects bone, we examined their influence on bone 
tissue mineral density, morphology, and mechanical properties at cortical and trabecular regions 
of the femoral bone in a transgenic mouse model. 
Whole bone strength is based on the combination of material properties (such as 
mineralization and extracellular matrix composition) (Burstein et al., 1975), microarchitecture 
(Galante et al., 1970; Ulrich et al., 1997), and total mass (bone volume) (Carter and Hayes, 1977). 
TMD was not significantly different among the sickle and control animals within the same age 
groups. This observation was contrary to clinical observations in which more than half of the 
pediatric and adult patients with SCD have low BMD, and may be due to the measuring of TMD 
or the utilization of a non-human model (Brinker et al., 1998; Fung et al., 2008b; Lal et al., 2006; 
Miller et al., 2006). However, previous studies have shown that healthy bone samples of different 
ages with the same TMD have variations in mechanical strengths due to different cortical and 
trabecular architectures (Galante et al., 1970; Ulrich et al., 1997). Bonnet et al., suggest that cortical 
thickness primarily contributes to the breaking force necessary while performing bending analysis 
(Bonnet et al., 2006). This finding supports the relatively similar mechanical forces demonstrated 
between genotypes in the younger femurs (with similar cortical area and thickness) as opposed to 
the nearly 40% reduction in forces necessary to deform and fracture older sickle bone (with 
diminished cortical bone area and thickness). Additionally, four-point bending generates 
compressive and tensile data that are not influenced by the load placed on specific sites of fragility, 
but rather the distribution of the load throughout the cortical and trabecular regions (Brodt et al. 
1999; Turner and Burr, 1993). 
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It has been previously reported that, with age, trabecular bone in men becomes fragile due 
to trabecular thinning while women suffer from loss of trabecular plates (Aaron et al., 1987). 
However, microCT analyses of sickle mouse femora suggested that SCD further confounds the 
natural deterioration of the trabeculae. The signature sickle bone characteristic of substantially 
increased bone marrow cavity was only observed in the metaphyseal region. This effect may be 
predominantly associated with decreased number of trabeculae and increased spacing, since 
trabecular thickness was similar between the genotypes. Furthermore, trabecular degradation of 
sickle bone with respect to age was drastically more apparent in the metaphysis than the epiphysis, 
potentially due to an increased risk of vaso-occlusion derived from the more abundant and 
independent vasculature of the metaphysis (Lewis, 1956). SMI provided further insight into the 
morphological differences of the trabecular structures across the genotypes and ages. Trabecular 
bone is expected to transition from more plate-like to more rod-like architecture as age-related 
bone loss and remodeling occurs (Hildebrand and Rüegsegger, 1997). However, sickle bone in the 
older animals had significantly more rod-like morphology than trait and wild-type animals, 
suggesting accelerated age-related structural changes. 
Altogether, even small alterations in the trabecular and cortical microarchitecture and 
reduction in bone volume observed in trait and sickle bone may have contributed to differences in 
mechanical properties, especially for older animals. Interestingly, AS and SS bone exhibited 
opposing material behaviors; the former tended to be more rigid while SS bone expressed a more 
flexible nature than both AA and AS. Additionally, increased flexibility of the diseased genotype 
in combination with the maintenance of TMD and significantly lower elastic modulus suggest that 
there may be differences in the material composition of sickle bone. 
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Collectively, mineralization and the architecture of the various bone regions establish a 
compensatory and dependent relationship to maintain essential mechanical functionality 
(Tommasini et al., 2008). Unfortunately, SCD serves as an intricate auxiliary condition to aging 
that produces unique whole bone phenotypes and behaviors. Overall, young sickle bone may 
exhibit relatively normal attributes of mineral content as well as cortical and metaphyseal 
trabecular bone; however, with aging the combined effect of vaso-occlusion and intrinsic factors 
alter the bone microarchitectural morphology resulting in abnormally flexible yet functioning 
sickle bone. The decrease in the amount of force required to deform sickle mouse femurs compared 
to wild-type and trait may be indicative of the self-reported low impact fracture incidences in both 
children and adults, implying that SCD results in chronic pathological fracturing (Arlet et al., 2013; 
Fung et al., 2008a; Omer et al., 2013). Clinical observations have illustrated that SCD patients are 
prone to have more bone deformities than fractures, thus supporting the malleability observed from 
the sickle and trait femurs (communication with Ifeyinwa Osunkwo, M.D.). It may be that with 
age, SCD augments the natural degradation of the tissue microarchitecture, resulting in a 
mechanically more inferior bone that is not comparable to its non-sickle peers. Further 
examination of the influence of SCD on bone microvasculature and biomechanics related to the 
material properties will advance our understanding of sickle bone pathophysiology, leading to the 




CHAPTER 4: THE LACK OF SEXUAL DIMORPHISM IN SICKLE BONE DUE TO 
HORMONAL DEFICIENCIES 
4.1 INTRODUCTION 
Although SCD is now considered a lifelong condition within developed countries, the 
majority of clinical and basic research does not reflect this sentiment. Studies typically focus on 
the adolescent or late adulthood manifestations of SCD, with roughly twice as many adolescent 
focused publications from 2000 to 2019. This influx mirrors the prioritization of pediatric 
healthcare for patients with SCD, which has markedly reduced childhood mortality to <10% in 
developed countries (Chaturvedi and DeBaun, 2016; Morris et al., 2006; Steinberg et al., 2003). 
Today, more than 90% of sickle patients reach adulthood, but the limited access and poor transition 
to specialized adult healthcare for these patients lead to a shortened lifespan of 42 years for males 
and 48 years for females (Paulukonis et al., 2016; Platt et al., 1994). Although the etiology of sickle 
mortality is associated with the accumulation of chronic organ damage, understanding how sex 
influences SCD pathology may help identify at which point healthy organ function converts to 
physiological inefficiency. 
  Puberty plays a pivotal role in skeletal growth and maturation (Saggese et al., 2002). The 
skeleton undergoes marked geometric changes and nearly doubles in mass from adolescence to 
adulthood, a transition most notably observed in males (Riggs et al., 1999; Seeman, 2001). The 
insulin-like growth factor 1 (IGF-1) system and sex hormones (eg. androgens and estrogens) are 
key regulators of skeletal maturity (Bouillon et al., 2004; Finkelstein et al., 1989; Marcus et al., 
2000; Smith et al., 2008, 1994). However, androgens are also converted into estrogen which, if not 
present, disrupts normal bone growth in males (Almeida et al., 2017). Estrogen binds and activates 
estrogen receptors on skeletal cells, specifically the ɑ-variation, to restrict or stimulate radial 
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expansion in females and males, respectively (Callewaert et al., 2010a; Couse et al., 1995; Vidal 
et al., 2000). In fact, it has been shown that estrogens may interact with the GH–IGF-1 axis in both 
humans and animals (Juul, 2001; Venken et al., 2006). Estrogen-related skeletal changes in male 
bone are associated with lower IGF-1 levels (Vanderschueren et al., 1997; Vidal et al., 2000).     
With respect to trabecular bone, serum IGF-1 does not appear to have the same influence 
it has on cortical bone (Yakar et al., 2009). However, one study demonstrates that the lack of IGF-
1 signaling in osteoblasts during the late pubescent growth period of mice (6 weeks of age) 
uncouples bone mineralization, resulting in significant decrease in trabecular bone (Zhang et al., 
2002). More conclusive evidence supports the notion that sex hormones are vital to trabecular 
growth and maintenance over time. Studies reveal that loss of estrogen in post-menopausal women 
leads to significant bone loss, or osteoporosis. This same age-induced loss of bone can also be 
observed in males, with an average onset of 75 years old compared to 65 years for women (Ebeling, 
2008). Studies have shown that orchidectomized mice or males lacking androgen receptors 
experience severely reduced trabecular bone mass with increased bone turnover (Callewaert et al., 
2009; Kawano et al., 2003; Venken et al., 2006). The vital role of androgen receptors in the 
maintenance of male trabeculae therefore mirrors the importance of estrogen receptor-ɑ signaling 
for preventing osteoporosis in female mice (Lindberg et al., 2001). Non-responsiveness from the 
administration of supraphysiological estrogen levels in orchidectomized mice supports the notion 
that androgen receptor activation is solely responsible for male trabecular bone development 
(Vandenput et al., 2001). 
A more comprehensive understanding of sex’s influence on sickle bone can provide 
additional knowledge on the pathophysiology of the disease and promote the development of new 
treatments. Few studies have reported growth delays in children with SCD, with males having a 
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marked delay in the onset of normal pubertal growth spurts (Phebus et al., 1984; Rhodes et al., 
2009). Whether or not the adult sickle body is affected by the delayed growth patterns is subject 
to controversy; some studies argue that young adults with SCD are shorter than their healthy peers 
(Ashcroft et al., 1972; Thomas et al., 2000; Zemel et al., 2007), while others demonstrate that they 
reach normal adult height (Kramer et al., 1980; Platt et al., 1984). It is notable that although sexual 
mortality differences in SCD patients become apparent in adulthood (around 30 years old), males 
are believed to have a higher incidence of pain and crises throughout adolescence following the 
onset of puberty (Baum et al., 1987; Platt et al., 1994, 1991). Hemoglobin concentrations increase 
by 2 g/dL in pubescent healthy males due to the surge of testosterone and IGF-1 (Hero et al., 2005). 
However, sickle males have reported as much as 50% less serum testosterone than controls in both 
humans (Abudu et al., 2011) and transgenic mice (Musicki et al., 2015). IGF-1 gradually increases 
total hemoglobin concentrations by stimulating erythropoiesis (Claustres et al., 1987; Kurtz et al., 
1988; Merchav et al., 1988). Collett-Solberg and colleagues demonstrate that children with SCD 
have abnormalities in the IGF-I axis, which worsens with age (Collett-Solberg et al., 2007).  
Previous studies involving the role of estrogen in SCD typically focus on its function of 
contraception in female patients or its relation to ovarian failure. On average, estrogen 
concentrations fall within normal range unless the patient suffers from a condition such as iron 
overload (Haddad et al., 2012; Hagag et al., 2016). An emerging body of work examines estrogen 
as a therapeutic agent that prevents vascular injury in SCD through the expression of the 
antioxidant, nitric oxide (Gladwin et al., 2003). Unfortunately, sickle male subjects show less nitric 
oxide basal expression than controls and are non-responsive to estrogen therapies. To the best of 
our knowledge, only one study has considered the effect of sex hormones on osteoporosis in SCD 
patients (Sadat-Ali et al., 2008). The authors state that approximately 60% of patients could be 
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categorized as osteopenic or osteoporotic at that time of examination. Interestingly, estrogen and 
testosterone levels show significant reduction for osteoporotic sickle females and males, 
respectively. Although the data seem to present a paradigm shift, the study does not consider the 
role of IGF-1 and growth patterns from adolescence, and also utilizes inherently variable DXA 
technology. To this end, the aim of the present study was to examine sex-specific differences in 
skeletal growth and development in relation to IGF-1 and the sex hormones within the context of 
SCD. 
4.2. Materials & Methods 
4.2.1 Animal Model 
We established a Townes (Wu et al., 2006) transgenic sickle mouse colony in our 
laboratory, as previously reported (Green et al., 2015). Mice were selectively mated and 
categorized into either homozygous βS-hemoglobin (SS) or homozygous βA-hemoglobin 
littermate controls (AA) as determined by PCR. Male and female mice were weighed and 
sacrificed at 4, 8, 12, and 16 weeks old (n=5/group) to be evaluated. All protocols are IACUC 
approved by The City College of New York. 
4.2.2. Hormone Levels in Plasma 
Blood was collected retro-orbitally in plasma separator tubes with Lithium Heparin from 
sickle mice at time of sacrifice (Becton Dickinson, Franklin Lakes, NJ, USA). Plasma 
concentrations of IGF-1, 17 𝛽-estradiol, and testosterone were determined via ELISA with 





MicroCT studies were performed to assess the growth and development of bone 
architecture of mice with SCD. Femurs were harvested at the time of sacrifice and fixed in a 10% 
formalin buffer before microCT, as previously reported (Cheung et al., 2016). Bones were scanned 
at 6.7-mm resolution with a SkyScan 1172 microCT system (SkyScan, Kontich, Belgium). Images 
were acquired using a 10-MP digital detector, at 100 KV and 100 mA and using a 0.5-mm 
aluminum filter. Flat-field calibration was performed before each scanning session. X-ray 
projections were generated from each sample at 0.3 degrees; 5 exposures per projection were taken 
(1767-ms exposure time). A global threshold was applied to images using grayscale values of 85 
and 70 for cortical and trabecular bone, respectively. Images were reconstructed to generate cross-
section images from X-ray projections (NRecon, Bruker, Billerica, MA, USA). Reconstruction 
procedures implemented a standard post alignment compensation algorithm to eliminate 
misalignment artifacts, and all reconstruction parameters (kernel size 1 for asymmetrical boxcar 
window, ring artifact 10, beam hardening 40%) were kept constant throughout each scan 
reconstruction. Measurements were performed at the mid-diaphysis cortex and the metaphyseal 
trabecular region. Properties will include total bone length, trabecular thickness (Tb.Th), trabecular 
number (Tb.N), bone volume (BV), and total volume (TV), as well as the cortical bone area 
(Ct.Ar), total area (Tt.Ar), cortical thickness (Ct.Th). 
4.2.4 Statistical Analysis 
Data were analyzed by analysis of variance (ANOVA) tests with a post-hoc t-test for 
pairwise comparison either between genotypes, sex, or age. All data are represented as mean ± 




4.3.1 Body Weight and Whole Bone Growth 
The total body weight of WT and SS males does not significantly differ with age until 16 
weeks, with SS males having approximately 14% less total mass than WT (p<0.05; Figure 4.1). 
With respect to female mice, SS had as much as 25% more mass than age matched controls from 
4 to 12 weeks of age (p<0.05). However, the sexual dimorphism of males being heavier than 
females was maintained in SS mice (Table 4.1). Longitudinal growth of male femurs did not differ 
amongst genotypes (Figure 4.2). SS females appear to have longer femurs than sex matched 
controls during skeletal adolescence (4-8 weeks) (p<0.05). At skeletal maturity, female femur 
lengths were even between genotypes but WT tibias were slightly longer than SS (p<0.05). The 
sexual dimorphism of WT appendicular whole bone lengths mirrors total body weight differences. 
Within SS mice, the sexual dimorphic difference is reduced from approximately 15% in WT 
specimens to 5% in femurs (p<0.05). In WT femurs, both male and females have comparable 
lengths at 16 weeks of age; however, this occurs earlier at 12 weeks in SS mice. Moreover, a 
sexually dimorphic difference in tibial bone length is maintained for the duration of the study but 
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Figure 4.1- Change in total body mass of male (blue closed circle)) and female (pink open 
circle) with respect to genotype and age. Controls (WT, solid line) and sickle (SS, dotted). 
* p<0.05 vs Female. $p<0.05 vs SS 
 





















































Figure 4.2 - Changes in femoral longitudinal (A) and radial (B) growth of male (blue 
closed circle) and female (pink open circle) with respect to genotype and age. Controls 




4.3.2 Cortical Bone 
The WT male Ct.Ar is significantly larger than that of WT females throughout the entirety 
of the study, with the area difference being nearly twice that of females (p<0.05; Table 4.1). The 
sexual dimorphism of Ct.Ar in sickle mice is not as markedly different during adolescence as it is 
in WT but disappears by skeletal maturity. Genotypic comparison, the SS male in ability to gain 
bone leads to comparable Ct.Ar to that of female WT and SS mice. Although WT Ct.Ar is sexually 
dimorphic, WT bone areal fraction of total area does not differ between males and females (Figure 
4.3). However, the reduced radial expansion of SS males leads to sexually dimorphic Ct.Ar/Tt.Ar 
phenotype at skeletal maturity. The reduction of WT male Ma.Ar with age is inversely related to 
its Ct.Th; which disagrees with the general increase of Ma.Ar and Ct.Th in WT and SS female 
mice (Figure 4.3). The increase in SS male marrow area may be directly related to the significant 
thinning of the cortex with age. Post-weaning Ct.Th does not differ amongst males, but SS males 
have approximately 20% thinner cortical bone at 12- and 16-weeks (p<0.05). However, pubescent 









































Figure 4.3- Sexual dimorphism of cortical bone in SS and WT mice. (A) Fractional bone 
area percentage. Controls (WT, solid line) and sickle (SS, dotted). * p<0.05 vs Female. 




4.3.3 Trabecular Bone 
The starting BV/TV ratio of WT males is twice that of females at 4 weeks old, but 
substantially increases to nearly five times the amount by skeletal maturity (p<0.05; Figure 4). 
There is no notable BV/TV sexual dimorphism in prepubescent SS mice, due to SS female having 
slightly larger bone volume than WT females. At 12 weeks SS female BV/TV decline towards WT 
levels creating a sexual dimorphism. SS male’s BV/TV ratio does not follow the same growth 
pattern of WT males, who occupy as much as 15% of the trabecular space. Interestingly, both WT 
and SS males maintained a higher Tb. No and Tb.Th (Table 3) than their respect female counterpart 
at all time points examined (p<0.05). However, SS males started to decrease in trabecular thickness 
at 12 weeks (p<0.05). Female mice showed a slight disagreement in trabecular microarchitecture 































Figure 4.4 – Sexual dimorphism of trabeculae bone volume content during growth and 
development for WT and SS (top). MicroCT representative images of male trabecular 
bone volume (bottom). Controls (WT, solid line) and sickle (SS, dotted). * p<0.05 vs 
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Tb.No 7.39 5.99 6.66 5.82 8.57 7.31 6.92 5.68 




(1/mm) (0.34) (0.45) (0.45) (0.35) (0.54) (0.48) (0.19) (0.23) 
4.3.4 Serum Hormones 
WT males steadily increase the expression of serum IGF-1 up to 12 weeks of age and 
maintained nearly two times the amount expressed in WT females (p<0.05; Figure 4.5). At 16 
weeks the roles were switched, WT female IGF-1 concentrations increased while male 
concentration was reduced by 50% (p<0.05). Initially SS males expressed similar concentrations 
of serum IGF-1 at 4 weeks but was substantially lowered to nearly half of WT males’ levels at 8, 
12, and 16 weeks (p<0.05). Female SS exhibited relatively similar or slightly elevated serum IGF-
1 levels to WT females but started to decline at 16 weeks (p<0.05). 
In regard to sex hormone expression, serum levels of 17𝛃-estradiol did not significantly 
vary amongst WT and SS female mice from adolescent to skeletal maturity (Figure 4.5). Post 
weaning (4 weeks) measurement of estradiol displayed some specimens with elevated estradiol 
levels increasing the mean concentration but was considered insignificant statistically. Male 
estradiol serum concentrations were also collected but did not vary amongst genotype nor age (data 
not shown).  
There was no notable difference in serum testosterone concentrations in WT and SS males 
at 4 weeks of age. The onset of puberty (~6 weeks) increased the overall amount circulating 
testosterone equally in WT and SS males at 8 weeks and remained relatively equal at 12 weeks 
(Figure 4.5). At the point of skeletal maturity, the mean concentration of WT testosterone was 































Figure 4.5 - IGF-1, testosterone, and estradiol expression during bone growth and 
development. Controls (WT, solid line) and sickle (SS, dotted). * p<0.05 vs Female. 





Compared to human skeletal physiology, mice undergo similar mechanisms of bone 
growth and development. In particular, the establishment of sexually dimorphic bone phenotypes 
at the onset of puberty from the subsequent hormonal changes permit the utilization of mouse 
model to study the impact of sex on SCD bone pathology. Bone undergoes both longitudinal and 
radial growth from adolescence to skeletal maturity (Clarke, 2008). Longitudinal growth occurs 
when the cartilage of the growth plate regions proliferates, thereby lengthening long bones, and 
subsequently mineralize to form new bone. In our study, male mice femurs are significantly longer 
than females until 16 weeks of age. The difference in femoral length between male and female 
sickle mice is not as large as it is in controls, but the dimorphism dissipates by 12 weeks. While 
there is no difference in male femoral length between genotypes, this departure from the sexually 
dimorphic control phenotype is due to adolescent SS females having longer femurs than control 
counterparts. However, SS females ultimately have the same adult femoral length as controls, 
mirroring clinical observations of height in SCD (Ashcroft et al., 1972; Thomas et al., 2000).  
Systemic hormonal regulation of longitudinal bone growth during adolescence includes 
thyroid hormones, and growth hormone (GH)-IGF-1 signaling. Thyroid hormone and GH-IGF 
signaling stimulates chondrocyte differentiation, facilitate vascularization and the recruitment of 
cells into the proliferating zone of the growth plate (Bikle and Wang, 2011; Kozhemyakina et al., 
2015). Meta-analyses report serum levels of thyroid hormone and GH generally do not vary in 
child with SCD although growth delays during puberty may be present, lasting 1 to 2 years on 
average (Nunlee-Bland et al., 2011; Rhodes et al., 2009; Zemel et al., 2007). GH has also been 
shown to induce IGF-1 expression systemically and locally within the bone (Le Roith et al., 2001). 
Liver specific IGF-1 knockout mice had 75% reduction in serum levels with similar longitudinal 
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bone growth rates as controls (Yakar et al., 2002, 1999). Despite the marked reduction of serum 
IGF-1, locally produced IGF in the growth plate is not affected by the model and may explain why 
normal longitudinal growth occurs (Parker et al., 2007; Sjögren et al., 1999; Yakar et al., 1999).  
Radial bone growth occurs through a process known as modeling, by which the overall 
shape of cortical bone changes in response to mechanical or physiological influences. Bone 
normally widens with age via periosteal apposition of new bone and endosteal resorption to 
accommodate the increase in body weight. In our study, both WT and SS male mice have 
significantly more total body weight than their female counterparts throughout the study, SS males 
do not maintain the same amount of femoral bone or thickness after 12 weeks of age. However, 
the 25% increase in SS female body weight may justify the thicker cortex observed during 
adolescence, but not at skeletal maturity where SS and WT do not differ. Disruption of modeling 
can be attributed to competing physiological inputs from adjacent and remote tissues that act on 
the skeleton in an endocrine and paracrine fashion (Ubara et al., 2005, 2003). This can be illustrated 
by the marked reduction of systemic IGF-1 on cortical bone microarchitecture. Yakar and 
colleagues’ initial work in a liver induced IGF-1 deficiency mouse model appeared to maintain 
normal longitudinal growth but proceeding microCT studies show significant cortical thinning and 
reduced mechanical properties (Yakar et al., 1999). The drastic decline of serum IGF-1 in SS males 
occurs in the vital period when sexual dimorphic phenotype of bone is established. Previous studies 
have shown that interruption of IGF-1 signaling during this period leads to indistinguishable male 
and female cortical bone microarchitecture (Callewaert et al., 2010a). Nonetheless, systemic IGF-
1 plays a negligible role in the establishing and maintenance of trabecular bone.  
It is generally accepted in humans that androgens contribute to the major differences in 
cortical and trabecular bone phenotypes between men and women (Iuliano-Burns et al., 2009; 
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Seeman, 2001). Estrogen receptor-α (ERα) signaling within chondrocytes at growth plate 
stimulate for longitudinal growth at the start of puberty and induce closing of the growth plates at 
its end (Börjesson et al., 2010). This phenomenon is predominantly mediated by estrogen in both 
females and males, whose testosterone is aromatized into estrogen is vital part of the process 
(Carani et al., 1997; Lanfranco et al., 2008). We have demonstrated that the serum estrogen levels 
of sickle female and male mice are comparable to that of controls during skeletal growth and 
development. The presence of normal estrogen concentrations in both sexes may further justify 
the importance of total body weight on longitudinal growth, with adolescent SS females briefly 
being heavier and having longer femurs than controls while males remained on par with each other. 
Numerous studies have also demonstrated that testosterone is largely associated with the 
increasing radial expansion of the cortex and estrogen limits periosteal bone formation, but 
removal of their respective hormone reverses the relationships (Gunness and Orwoll, 1995; 
Schoutens et al., 1984; Turner et al., 1989; Wronski et al., 1985; Zhang et al., 1999). Normally 
male mice gradually increase testosterone production to facilitate reproductive maturity at 6 weeks 
and reach peak levels around 15 weeks (Clarkson and Herbison, 2016; Wang et al., 2015). With 
respect to bone, Callewaert and their peers demonstrated that testosterone contributes to cortical 
bone size around the onset of puberty (5 to 8 weeks) working with IGF-1 to establish the sexually 
dimorphic phenotype (Callewaert et al., 2010b).  The mean concentration of serum testosterone 
did not vary between WT and SS mice until 16 weeks of age, suggesting that IGF-1 predominantly 
affects SS male cortical bone development. 
Androgen deficiency is linked to age-related trabecular bone loss in humans and animal 
models for both males and females. Osteoporosis is commonly known to occur after 
postmenopausal reductions of estrogen, but men experience similar loss at a slower rate due to 
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testosterone concentrations lowering much later in life (Ebeling, 2008). The biochemical changes 
to osteoclastogenesis and osteoblast activity of castrated males leads to the same pro-resorption 
microenvironment of the trabeculae observed in postmenopausal women and ovariectomized mice 
(Manolagas, 2000). SS male mice failed to elevate mean serum testosterone beyond baseline 
concentrations, being nearly 13% of control levels. Trabecular bone mass of WT males gradually 
increases to peak number and thickness at 12 weeks in our study and previous models (Ferguson 
et al., 2003). Although mean concentrations of adolescent WT serum testosterone are not 
statistically different from SS males, individual consideration shows a trend of increasing serum 
levels. However, stagnant levels in SS male testosterone throughout this study reflects the lack of 
change in trabecular bone volume.  
Our data suggest that SCD hinders IGF-I and testosterone secretion, disrupting the normal 
course of skeletal maturation in male mice, while females are largely unaffected. Conditional 
knockout studies suggest that circulating IGF-1 helps maintain cortical and trabecular thickness as 
late as 15 months of age (Ashpole et al., 2016; Courtland et al., 2011). Xiao and colleagues report 
that 24-week-old sickle female mice have marked osteopenia due to the lack of sufficient systemic 
expression and local IGF-1 signaling (Xiao et al., 2016). Exogenous delivery of IGF-1 to sickle 
bone marrow osteoblasts in vitro recovers activity level to that of controls.  We observed the 
reduction of serum IGF-1 in SS females at 16 weeks, but it is unclear whether IGF-1 concentrations 
continue to decrease with age. Given the antioxidant and anti-inflammatory effects of IGF-1, 
further study is needed to determine the mechanism of IGF-1 reduction and develop therapeutic 
strategies (Higashi et al., 2010; Holzenberger et al., 2003; Sukhanov et al., 2007). 
The relationship between bone and iron metabolism is of particular interest due to the high 
incidence of osteopenia and osteoporosis in patients with hemoglobinopathies (Vogiatzi et al., 
 
61 
2009; Weinberg, 2008). Within healthy populations the role of iron status in bone metabolism is 
inconclusive; however, there are numerous reports of osteopathic manifestations in regard to 
patients with iron overload and deficiency (Buyukbese et al., 2005; Kim et al., 2012; Lee et al., 
2014). Iron overload is most commonly associated with repeated blood transfusions throughout 
the course of a patient's life (ie. sickle cell anemia and 𝛽-thalassemia) and the subsequent oxidative 
damage from the retention of excess iron within tissue. Studies have shown that non-transfusional 
iron storage occurs within the liver, lungs, and kidneys of mice with SCD in the form of 
hemosiderin (Nguyen et al., 2014). The hemosiderin within the liver is largely stored in Kupffer 
cells that are responsible for the uptake of senescent red blood cells (Fleming and Bacon, 2005; 
Raghupathy et al., 2010; Wu et al., 2006). Moreover, the presence of iron within a tissue leads to 
dysfunction such as impaired IGF-1 secretion from the liver (De Sanctis et al., 2015). Bone itself 
is capable of storing excess iron, resulting in substantial cortical and trabecular resorption (Tsay 
et al., 2010). Treatment with the antioxidant N-acetyl-L-cysteine prevents bone loss, suggesting 
oxidative stress as the pathological mechanism.  
Evidence supporting how iron deficiency affects bone includes the disruption of bone 
extracellular matrix collagen formation (Kular et al., 2012) , the withdrawal of iron as a 
cytochrome cofactor in vitamin D metabolism (Jones et al., 2014), and the pro-resorptive influence 
of hypoxia on bone cell physiology (Arnett et al., 2003; Shiozawa et al., 2010). Iron deficiency 
appears to be the norm in patients with SCD based on serum ferritin, serum transferrin, and iron-
binding content of bone marrow aspirates (Rao et al., 1983; Vichinsky et al., 1981). This 
methodology may not be ideal for SCD in that circulating iron status varies based on numerous 
factors including sex, crises, age, haplotype, diet, and menstrual cycle (Koduri, 2003). 
Coincidentally, the liver is the primary source of iron needed for bone marrow erythropoiesis and 
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its dysfunction can lead to iron deficient marrow and overall anemia. In the context of SCD, the 
supranormal amounts iron found in the liver of both human and animal models may alter the 
transfer of iron to the marrow (Maher and Mansour, 2009; Mills et al., 1988; Nguyen et al., 2014; 
Wu et al., 2006). Interestingly, studies have shown that oxidative stress reduces liver expression 
of IGF-I delays the initiation of puberty as well as the production of testosterone; supporting the 
notion that the relationship between liver and iron may influence androgen regulation of bone 
development (Musicki et al., 2015; Keene et al., 2002).  
In summary, we demonstrate that the sexually dimorphic maturation of bone 
microarchitecture is disrupted in sickle cell disease. Femoral cortical and trabecular features of 
sickle males are significantly diminished in conjunction with the reduction of serum IGF-1 and 
testosterone from puberty to skeletal adulthood, insinuating a failure to gain new bone with age. 
While female sickle mice appear to have larger bones than sex-matched controls during 
adolescence due to increased body weight rather than hormonal differences. There is no difference 
in female femoral microarchitecture at skeletal maturity, but the decline of IGF-1 may lead to bone 
resorption with age based on outside studies. Overall, this study suggests there is an intrinsic 
pathological difference between male and females with sickle cell disease and further in-depth sex 
specific assessment in necessary. 
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CHAPTER 5: THE INFLUENCE OF L-GLUTAMINE THERAPY ON SICKLE BONE 
GROWTH AND DEVELOPMENT 
5.1 Introduction 
Although the recent FDA approval of L-Glutamine (GLN) for patients with sickle cell 
disease (SCD) is a welcomed advancement, opposing research has led to uncertainty about its 
therapeutic mechanism and long-term safety. GLN was first considered as a therapeutic interest 
for SCD as an “antisickling” agent in 1975 after it was believed to revert sickle RBC shape while 
in suspension in vitro (Rumen, 1975). Whole blood studies suggested that GLN delays HbS 
gelation (Shirahama et al., 1980) and plasma proteins may reduce GLN bioavailability (Mackenzie 
et al., 1976). Separate investigations to measure the concentrations of GLN in sickle RBC can vary 
from supranormal levels (Kiessling et al., 2000) to deficiency in sub-population of sickle patients 
with a tricuspid regurgitant jet velocity (Morris et al., 2008). 
Today GLN, or commercially known as Endari, is believed to “reduce the acute 
complications of SCD by increasing the antioxidant capacity of sickle RBCs” (Niihara et al., 2014, 
1998). The proposed therapeutic mechanism is based on the initial work led by Kouicki Tanaka 
reporting that an increase in total NAD in sickle RBCs significantly lowers the reduced 
nicotinamide (NADH) to total NAD compared to normal controls (Zerez et al., 1988). The same 
group later reported that GLN is readily transported into sickle RBCs and increases NAD synthesis 
based on elevated concentrations of glutamate, a NAD synthesis by-product, within the RBCs 
(Niihara et al., 1997). Follow up studies mirrored the increase in NAD redox potential as well as 
endothelial adhesion (in vitro) after four weeks of therapy in patients with SCD, but the amount of 
free Hb and reticulocytes did not change, suggesting the drug did not influence hemolysis (Niihara 
et al., 2016, 2005) 
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Clinical trials of GLN for SCD were completed in 2014, with a primary outcome measuring 
the number of sickle crises (i.e. vaso-occlusive related painful events, acute chest syndrome, acute 
splenic sequestration, and priapism) within a 48-week period (Niihara et al., 2018, 2016). Although 
there were high withdrawal rates for both placebo (~60%) and treatment groups (~50%), GLN was 
associated with nominal reductions in patient hospitalizations due to crises. RBC morphology was 
also reported to improve during treatment but circulating Hb concentrations and reticulocyte count 
remained unaltered. There were 3 deaths in the GLN arm of the clinical trials, of which were 
associated with multiorgan related failures and deemed unrelated to the study by the investigators. 
Although patients with renal insufficiency and liver disease were excluded from the clinical trials, 
prior outside studies have shown that exogenous GLN is fatal to critically ill patients with multi-
organ failure (Heyland et al., 2013)). To our knowledge, the patients who died did not have a prior 
history of renal or liver impairment before the study, but no information exists as to whether a 
history of organ dysfunction is of concern for GLN therapy in SCD. Albeit reasonably tolerable 
short-term, the long-term effects of GLN are unknown in this population that are innately at risk 
of multiorgan failure. 
As stated above, GLN is a major source of glutamate which is vital for the synthesis of 
glutathione (GSH), a key tissue antioxidant. Researchers believe this to be the therapeutic 
mechanism within RBCs, but it has been shown that nearly 90% of RBC glutamate stems from a-
ketoglutarate and alanine (Ellinger et al., 2011). Nevertheless, GLN plays a vital role throughout 
the body and the benefit experienced by sickle patients may be explained by other means that have 
yet to be explored. Bone tissue is of particular interest due to its sensitivity to oxidative stress and 
the utilization of osteocytes to understand the effect of long-term therapies on cells and tissue 
(Abdollahi et al., 2005; Wauquier et al., 2009).  
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With respect to SCD, we have previously demonstrated that bone growth and development 
is hindered in sickle male mice due to insufficient testosterone and liver derived insulin like growth 
factor (IGF-1) (Chapter 5). Outside studies demonstrate a significant decrease of IGF-1 expression 
within sickle bone tissue as well (Xiao et al., 2016). Under normal conditions, the liver is one of 
the primary sources of GLN for the body, but disease and inflammation can turn the liver into a 
site of consumption (Cruzat et al., 2018). Hepatic GLN metabolism is associated with ammonia 
detoxification and blood pH regulation (Häussinger, 1997; Häussinger and Schliess, 2007). 
Acidosis is recognized as a promoter of RBC sickling with approximately 90% efficiency at pH 
7.0 in vitro (Chatel et al., 2018). Alternatively, studies have shown that the progressive tissue 
damage in SCD is correlated with the decrease in antioxidant response due to hemolysis derived 
oxidative stress (Ghosh et al., 2016). Assuming GLN is associated with increasing GSH synthesis, 
the liver may benefit from this increased antioxidant capacity. Presumptively, we hypothesize that 
GLN therapy ameliorates sickle bone growth defects by increasing liver expression of IGF-1. 
5.2 Materials & Methods 
5.2.1 Animal Model 
We established a Townes (Ryan et al., 1997; Wu et al., 2006) transgenic sickle mouse 
colony in our laboratory, as previously reported (Green et al., 2015). Mice were selectively mated 
and categorized into either homozygous βS-hemoglobin (SS) or homozygous βA-hemoglobin 
littermate controls (WT) as determined by PCR. GLN supplementation was given ad libitum via 
drinking water (1g/kg) from weaning (3 weeks old) until the time of sacrifice. Male mice were 
weighed and sacrificed at 4, 8, 12, and 16 weeks old (n=5/group) to be evaluated. All protocols 
are IACUC approved by The City College of New York. 
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5.2.2. Redox Potential 
Blood was collected retro-orbitally at time of sacrifice and immediately processed to 
determine redox potential according to manufacturer's protocols (BioAssay Systems, Hayward, 
CA, USA). Briefly, blood samples and standards were mixed with an MTT-based working reagent 
in wells of a 96-well plate, from which optical density values were obtained at time 0 and following 
a 15-minute incubation period at 25°C. A standard curve using NAD concentrations of 0, 3, 6, and 
10 μM was created for each assay. Cellular redox potential was calculated as the ratio of NADH 
to total NAD+ (NADH and NAD+) as reported by Niihara and colleagues (2014). Freshly 
reconstituted reagents were used for each assay.  
5.2.3. Blood Plasma Composition 
Plasma was isolated from whole blood in Lithium Heparinized separator tubes (Becton 
Dickinson, Franklin Lakes, NJ, USA). Plasma protein concentrations of IGF-1, hemopexin (HPX), 
17𝞫-estradiol, and testosterone were determined via ELISA with sensitives of 0.1ng/mL, 4.51 
ng/mL, 8.68 pg/mL, and 0.07 ng/mL respectively (Abcam, Cambridge, MA, USA). Plasma GLN, 
hemolysis associated lactate dehydrogenase (LDH), and liver glutamyl transferase (GGT) activity 
were measured via colorimetric assays with detection miminums of 25 μM, 1 µU/mL, and 0.5 mIU 
respectively (Abcam, Cambridge, MA, USA). All protocols were conducted according to the 
manufacturer's instructions. 
5.2.4. Organ Masses 
Abdominal organs (spleen, liver, and kidneys) were isolated at the time of sacrifice and 
weighed. Splenomegaly was used to stratify GLN data as responsive (GLN+) or unresponsive 
(GLN-) as spleen size provides a “clinical index” for therapeutic efficacy in SCD.  
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5.2.5. Tibia MicroCT 
MicroCT studies were performed to assess the growth and development of bone 
architecture of mice with SCD. Tibias were harvested at the time of sacrifice and fixed in a 10% 
formalin buffer before microCT, as previously reported (Cheung et al., 2016). Bones were scanned 
at 6.7-mm resolution with a SkyScan 1172 microCT system (SkyScan, Kontich, Belgium). Images 
were acquired using a 10-MP digital detector, at 100 KV and 100 mA and using a 0.5-mm 
aluminum filter. Flat-field calibration was performed before each scanning session. X-ray 
projections were generated from each sample at 0.3 degrees; 5 exposures per projection were taken 
(1767-ms exposure time). A global threshold was applied to images using grayscale values of 85 
and 70 for cortical and trabecular bone, respectively. Images were reconstructed to generate cross-
section images from X-ray projections (NRecon, Bruker, Billerica, MA, USA). Reconstruction 
procedures implemented a standard post alignment compensation algorithm to eliminate 
misalignment artifacts, and all reconstruction parameters (kernel size 1 for asymmetrical boxcar 
window, ring artifact 10, beam hardening 40%) were kept constant throughout each scan 
reconstruction. Measurements were performed at the mid-diaphysis cortex and the metaphyseal 
trabecular region. Properties will include total bone length, trabecular thickness (Tb. Th.), 
trabecular number (Tb.N.), bone volume (BV), and total volume (TV), as well as the cortical bone 
area (BA), total area (TA), cortical thickness (Ct.Th.).  
5.2.6. Tibia Mechanics 
Tibial mechanical properties were measured via three-point bending with a Bose 
Electroforce mechanical testing system as previously reported (Turner and Burr, 1993). Briefly, 
thawed and hydrated tibiae were placed on support pins spaced 9 mm wide with radius of curvature 
0.6 mm while a load was applied at a rate of 0.05 mm/s until failure (Fig 1.) Tibiae were tested in 
the anterior-posterior plane where the upper pin was centered on the posterior side of the mid-
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diaphyseal location scanned by micro-CT. The force and deflection data obtained from the Bose 
system were used to calculate stiffness, yield force, post yield deflection (PYD), and work to 
failure. The yield point was defined with a 10% reduction of secant slope from the linear region of 
the force-deflection curve. The force-deflection data were normalized using the moment of inertia 
data obtained from the micro-CT analyses to calculate stress (σ) and strain (∈) with equations (1) 
and (2) respectively; where F = applied force, d = displacement, c = 1/2 of anterior–posterior axis, 
I_ml = 2nd moment of area about the medial–lateral axis, L = distance between the lower supports 








Manually dissected tibias free of soft tissues were fixed in 10% formalin, and polymethyl 
methacrylate embedded before being cut longitudinally at 5µm thickness. Sections were stained 
with toluidine blue for general histology to determine the percentage of osteoid surface (OS/BS), 
osteoblast surface (Ob.S/BS), osteoclast surface (Oc.S/BS), eroded surface (ES/BS), osteoid 
thickness (OS.Th), osteocyte density (Ot.Den) and sinusoidal area (Sin.A). Toluidine blue is a 
metachromatic dye that selectively stains acidic tissue components including nucleic acids, 
sulfates, carboxylates, and phosphate radicals. Metachromatic stacking is the aggregation of 
cationic dyes at regions of high anionic concentrations that are represented by physical changes in 
color. Visual representation of stacking is generally represented by three colors associated with 
the degree of dye aggregation: blue (negative - monomeric), purple (dimeric), and red (polymeric). 
Additional staining includes Prussian blue for the detection of ferric iron content in the marrow, 
and 8-hydroxy-2'-deoxyguanosine as a biomarker of oxidative DNA damage. All procedures were 
performed according to manufacturer's instructions (Abcam, Boston, Massachusetts, USA). 
5.2.8. Bone Marrow Culture of Osteoblasts and Osteoclasts  
Bone marrow derived osteoblasts and osteoclasts were isolated from femurs at time of 
sacrifice and cultured as previously reported (Maridas et al., 2018). Briefly, the distal and proximal 
ends of the femur were removed, and the marrow was extracted through centrifugation. Pelleted 
marrow was resuspended in complete media (αMEM with 10% FBS and 1% 
Penicillin/Streptomycin) and plated a density of 10^6 cells/cm2 and allowed to attach. After 48 
hours, unattached cells (osteoclast precursors) are removed and replaced with fresh media every 
other day until cells are confluent. Osteoblasts were then cultured in differentiation media (1 M β-
glycerol phosphate and 0.5 M ascorbic in culture media) for 21 days. Alkaline phosphatase 
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concentration over total protein content was used to determine the osteogenic potential as done by 
Majeska and colleagues (Majeska et al., 1985). 
The non-adherent cells are cultured in osteoclast differentiation media (25 µg/mL of 
Receptor Activator of NFKB Ligand (RANKL) and 25 µg/mL of macrophage Colony Stimulating 
Factor (mCSF) added to complete media) for 5-7 days, replenishing differentiation media every 
other day. Media was supplemented with either 1, 2, or 4 mM GLN to determine its influence on 
osteoclastogenesis. Tartrate-resistant acid phosphatase (TRAP) positively stained multinucleated 
cells were counted at the end of the culture period (Millipore-Sigma, St. Louis, Missouri, USA).  
5.2.9. Osteocyte Enriched Cortical Gene Expression 
Total RNA was isolated from the aforementioned marrow evacuated femurs. Bones were 
manually cleaned to remove periosteum and any remaining tissue (ie. muscle), and immediately 
placed on ice or flash frozen in liquid nitrogen until RNA isolation. Frozen samples were 
pulverized using a mortar and pestle.  RNA was extracted using Trizol and RNeasy-mini kit 
(Qiagen). mRNA purity and concentration were measured with Take3 Microvolume 
spectrophotometer (Biotek) before being reverse transcribed into cDNA (Invitrogen). A custom 
RT2 profiler PCR Array was designed to assess genes associated with bone physiology, 
inflammation, and oxidative stress (Table 5.1). Gene expression data were normalized against the 
endogenous control genes βactin (Actb) and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH). The comparative (ΔΔCT) method was used to calculate the relative quantification of 
gene expression. Relative changes in gene expression were expressed as fold changes on a log 
scale compared to WT control. A log fold change of 1 represents a 10-fold increase in gene 












5.2.10. Statistical Analysis 
Data were analyzed by analysis of variance (ANOVA) tests with a secondary Dunnett test, 
comparing untreated SS and GLN treated mice to controls with their respective timepoints. All 
data are represented as mean ± standard deviation. A p-value <0.05 was considered statistically 
significant. 
5. 3 Results 
5.3.1. Redox Potential & Plasma GLN 
Initial plasma GLN concentrations show that SS mice have 40% more GLN than WT, but 
subsequent measurements at 8, 12, and 16 weeks demonstrate relatively normal plasma levels. SS 
mice were exposed to GLN treatment for four weeks post-weaning before measuring therapeutic 
efficacy (Figure 5.2). Surprisingly, GLN treated mice displayed a 75% reduction in plasma GLN 
levels at 8 weeks (p<0.05). Mean plasma levels steadily increased in GLN treated mice to having 
nearly 80% more bioavailable GLN than WT controls (p<0.05). Redox potential, the ratio of 
NADH to total NAD (NAD+ and NADH), increases with GLN therapy in SS mice, recapitulating 
Table 5.1 - Osteocyte physiology PCR primer sequences. 
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the clinical observations of Niihara and colleagues (Figure 5.2). GLN therapy allows SS mice to 
maintain a relatively normal redox potential at all time points, avoiding as much as a 70% 
difference at 8 weeks. It is noteworthy that untreated SS group did demonstrate an increase in 
redox potential with age and was within range of WT controls at 16 weeks.  
 
 


























Figure 5.2 - Blood Plasma Glutamine and Redox Potential. Controls (WT, solid black 
solid line), sickle (SS, open red solid line), and glutamine (GLN+, open blue dotted line). 








5.3.2. Organ Masses & Plasma Protein Composition 
Splenomegaly is an innate feature of SCD that is apparent in the mouse model early on in 
life and worsens with age (Figure 5.3). GLN treatment was systemically effective at 8 weeks, 
limiting the innate splenomegaly of untreated SS mice by reducing spleen mass by nearly 85% 
(p<0.05). At 12 weeks, GLN effects split into two groups: (1) maintained small spleens (GLN+), 
or (2) those with splenomegaly (GLN-), consistent with loss of GLN effect in these mice. GLN+ 
subgroup of SS mice maintained a reduced splenomegaly for the duration of the study, while GLN- 
subgroup exceeded the mean mass of untreated SS spleens by 30% at 16 weeks. The hepatomegaly 
of SS mice follows a similar therapeutic trend to the spleen with initial reductions in size at 8 
weeks and bifurcation at 12 weeks (Figure 5.3). GLN+ livers continue to decrease in size overtime 
until they are comparable to WT controls at 16 weeks. However, the unresponsive GLN- liver 
acquires 28% more mass than untreated SS mice at 12 weeks but settles at an intermediary size 






























































GLN treated SS mice inversely reflected the reduction in spleen size with a ~2-fold increase 
in IGF-1 plasma concentrations at 8 weeks, subsequently having approximately 20% more IGF-1 
in circulation than WT (p<0.05; Figure 5.4). There was a mean 50% difference in plasma IGF-1 
levels between GLN+ and GLN- at 12 and 16 weeks (p<0.05). GLN therapy also disrupts the trend 
seen at 8, 12 and 16 weeks in both untreated SS and controls, in that IGF-1 concentrations decrease 
from the initial surge at 8 weeks but increase to their normal levels, albeit with respect to WT 
(GLN+) and untreated SS (GLN-). GLN therapy increases the amount of plasma HPX available in 
SCD (Figure 5.4). Untreated SS mice fail to exhibit more HPX beyond the amount measured at 4 
weeks. However, GLN+ mice are shown to have nearly 95% the amount HPX observed in WT 
Figure 5.3 - Hepatosplenomegaly and impact of GLN in SCD. Controls (WT, solid 
black solid line), sickle (SS, open red solid line), glutamine positive (GLN+, open blue 
dotted line), and glutamine negative (GLN-, open green dot dashed line).  




plasma (p<0.05). At 16 weeks, mean HPX levels of GLN- was equal to that of untreated SS, while 
GLN+ remained at intermediary levels. 
Plasma testosterone remains unaltered with age and puberty in untreated SS mice (Figure 
5.4). Interestingly, GLN therapy appears to drastically increase plasma testosterone at 8 weeks 
after the initial 4-week exposure. However, the subsequent measurements show mean 
concentrations below that of untreated SS for both GLN+ and GLN- mice. Sickle mice fail to reach 



























Figure 5.4 - Blood plasma composition of IGF-1, testosterone, and estradiol after GLN 
therapy. Controls (WT, solid black solid line), sickle (SS, open red solid line), 
glutamine positive (GLN+, open blue dotted line), and glutamine negative (GLN-, 














































5.3.3. Tibial MicroCT 
Fractional bone area of untreated SS mice does not differ from WT and GLN treated mice 
until 12 weeks of age (Figure 5.5). This difference is due to a 3-fold increase in cortical marrow 
area and the subsequent decrease of cortical bone thickness of SS untreated (Table 5.2). GLN 
therapy was effective at 8 weeks, preventing cortical bone thinning in SS mice (p<0.05, Figure 
5.5). After 12 weeks, cortical bone in GLN+ mice group were similar to WT, while the cortex of 
GLN- mice were comparable to untreated SS mice. With respect to trabecular bone, GLN treated 
mice exhibited an intermediary trabecular mass between WT and untreated SS mice (Figure 5.5). 
The increase in bone volume fraction is primarily due to the 20% thicker trabeculae found in GLN 
treated sickle mice (p<0.05). At 16 weeks, a region of thin trabeculae that is seen in untreated SS 












Figure 5.5 - Longitudinal changes in cortical and trabecular bone content in SCD GLN 
therapy. Controls (WT, solid black solid line), sickle (SS, open red solid line), glutamine 
positive (GLN+, open blue dotted line), and glutamine negative (GLN-, open green dot 
dashed line). * p<0.05 vs WT. # p<0.5 vs SS 


































































AGE (WEEKS) 4 8 12 16 
Tt.Ar (mm2) 1.255 (0.435) 1.128 (0.065) 1.178 (0.078) 2.399 (0.263) 
Ct.Ar (mm2) 0.403 (0.029) 0.637 (0.031) 0.704 (0.036) 0.756 (0.092) 
Ma.Ar (mm2) 0.852 (0.428) 0.491 (0.045) 0.474 (0.048) 1.642 (0.181) 
Ct.Th (mm) 0.129 (0.012) 0.175 (0.011) 0.193 (0.005) 0.197 (0.021) 
BV/TV (%) 3.39 (1.73) 3.41 (1.18) 4.61 (1.11) 4.17 (1.10) 
Tb.Th (mm) 0.039 (0.007) 0.041 (0.007) 0.066 (0.008) 0.052 (0.006) 
Tb.N (1/mm) 6.43 (0.64) 5.81 (0.34) 5.50 (0.47) 5.31 (0.23) 
Sickle 
AGE (WEEKS) 4 8 12 16 
Tt.Ar (mm2) 1.121 (0.325) 1.118 (0.119) 2.104 (0.199) 1.848 (0.178) 
Ct.Ar (mm2) 0.419 (0.051) 0.604 (0.078) 0.621 (0.071) 0.565 (0.061) 
Ma.Ar (mm2) 0.702 (0.337) 0.514 (0.048) 1.483 (0.129) 1.283 (0.141) 
Ct.Th (mm) 0.136 (0.015) 0.165 (0.014) 0.169 (0.010) 0.163 (0.019) 
BV/TV (%) 3.64 (1.01) 3.58 (1.78) 2.99 (0.72) 2.42 (0.42) 
Tb.Th (mm) 0.038 (0.009) 0.045 (0.012) 0.044 (0.002) 0.046 (0.005) 
Tb.N (1/mm) 6.52 (0.76) 5.62 (0.45) 5.42 (0.14) 4.67 (0.25) 
GLN+ 
AGE (WEEKS) 4 8 12 16 
Tt.Ar (mm2) - 1.171 (0.279) 1.595 (0.032) 2.086 (0.194) 
Ct.Ar (mm2) - 0.610 (0.092) .624 (0.012) 0.670 (0.014) 
Ma.Ar (mm2) - 0.561 (0.320) .971 (0.020) 1.415 (0.208) 
Ct.Th (mm) - 0.183 (0.025) .208 (0.006) 0.203 (0.009) 
BV/TV (%) - 4.93 (3.65) 4.45 (0.102) 3.24 (0.965) 
Tb.Th (mm) - 0.043 (0.014) 0.05 (0.002) 0.052 (0.001) 
Tb.N (1/mm) - 6.57 (0.350) 5.68 (0.212) 4.92 (0.668) 
GLN- 
Table 5.2 – MicroCT of tibia mid-diaphyseal cortical and proximal metaphyseal 
trabecular bone quality metrics. 
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AGE (WEEKS) 4 8 12 16 
Tt.Ar (mm2) - - 2.023 (0.197) 2.081 (0.097) 
Ct.Ar (mm2) - - 0.607(0.023) 0.638 (0.045) 
Ma.Ar (mm2) - - 1.415 (0.202) 1.415 (0.061) 
Ct.Th (mm) - - 0.163 (0.007) 0.172 (0.006) 
BV/TV (%) - - 4.14 (1.08) 2.85 (0.578) 
Tb.Th (mm) - - 0.05(0.004) 0.047 (0.004) 
Tb.N (1/mm) - - 5.59 (0.187) 4.98 (0.33) 
 
5.3.4. Tibial Mechanics 
Tibiae were evaluated via three-point bending to determine the mechanical properties 
relative to genotype and GLN treatment status at 16 weeks of age (Table 5.3). GLN therapy 
increases tibial stiffness in sickle bone as much as 25%, with GLN+ mice being comparable to 
WT controls (p<0.05, Table 5.3). Maximum load reflects splenomegaly differences in that 
untreated SS and GLN- mice demonstrated approximately a 20% reduction in comparison to WT 
and GLN+ tibiae (p<0.05). A reduction of PYD by nearly 45% is observed in sickle mice while 
under GLN therapy (p<0.05). Work to failure within the tibia does not differ between WT and 
untreated SS, however the consideration of post-yield behavior suggests untreated SS tibia is more 
ductile than WT controls. The ductility of SS bone is maintained with GLN therapy, but the overall 
energy needed to fracture the tibia is reduced by 15-20% (p<0.05). Tissue-level mechanical 
properties of the tibia suggest a difference in sickle bone material composition as a result of GLN 
therapy. The increase in GLN+ modulus can be mostly attributed to the nearly 20% increase in 




Figure 5.7 - Representative force-displacement curves of tibial three-point bending. WT 
(black), SS (red), GLN+ (blue) and GLN- (green).  
 
Table 5.3 - Tibial fracture mechanics of GLN therapy at 16 weeks. 
MECHANICS WT SS GLN+ GLN- 
Stiffness (N/mm) 102.92 (7.52) 80.57 (0.95) 100.95 (1.65) 87.37 (1.51) 
Max Force (N) 17.63 (0.94) 14.24 (0.72) 16.78 (0.23) 13.93 (0.42) 
PYD (mm) 0.35 (0.11) 0.70 (0.09) 0.39 (0.19) 0.44 (0.06) 
Work (Nmm) 6.26 (0.55) 6.82 (0.71) 5.33 (0.94) 5.39 (0.1) 
Yield Stress (MPa) 150.56 (9.16) 177.97 (11.04) 185.06 (2.79) 139.33 (4.15) 
Ultimate Stress (MPa) 155.29 (7.11) 189.91 (10.39) 196.32 (4.67) 144.17 (5.04) 
IML 0.226 (0.025) 0.113 (0.031) 0.156 (0.033) 0.125 (0.054) 
 
5.3.5. Histology 
General histology (toluidine blue) agrees with microCT observations of reduced trabecular 
volume and cortical thinning, but provides further insight to bone surface activity, osteocytes 
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density, and sinusoidal content (Table 5.4). SS mice have relatively similar osteoid coverage as 
WT. However, GLN therapy reduces OS/BS by 50% as well as lowers OS.Th up to 40% in SS 
mice (p<0.05). Ob.S/BS does not significantly vary amongst genotype or treatment status. Mean 
Oc.S/BS of SS and GLN treated mice was higher than WT controls, but the WT ES/BS was nearly 
twice that of SS mice (p<0.05). Osteocyte density (Ot.Den) of SS mice was higher than WT 
controls, and GLN therapy furthers this difference up to 30% (p<0.05, Figure 5.8). However, WT 
mice have three times the amount of trabeculae bone available than SS mice, supporting an overall 
higher total number of osteocytes in comparison to SS and GLN+/- mice (p<0.05). Marrow 
sinusoidal content of SS mice is significantly larger than WT and GLN groups. The Sin.A, in 
GLN+ mice is similar to that of controls, but GLN- mice is reduced significantly further (p<0.05). 
This reduction in size may be related to reduced marrow volume subsequent to the void spaces 
appearing throughout the marrow. 
SS mice show nearly 40-fold difference in the amount of ferric iron present in WT bone 
marrow (p<0.05). GLN therapy leads to a 10-fold and 2-fold increase in iron content for GLN+ 
and GLN- mice respectively (p<0.05). There appears to be a notable difference in the location of 






Table 5.4 - Bone surface indices of sickle bone and GLN therapy. 
 
 WT  SS  GLN+  GLN- 
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OS/BS (%) 5.47 ± 1.09  4.06 ± 0.48  2.52 ± 0.42  1.89 ± 0.53 
O.Th (μm) 4.22 ± 0.71  3.78 ± 1.45  2.62 ± 0.58  2.61 ± 0.82 
Ob.S/BS (%) 6.15 ± 0.66  5.75 ± 0.75  5.51 ± 1.61  7.61 ± 0.97 
Oc.S/BS (%) 2.29 ± 0.53  2.69 ± 0.66  4.23 ± 1.29  2.82 ± 0.83 
ES/BS (%) 4.32 ± 1.15  1.98 ± 0.63  2.07 ± 0.86  2.41 ± 0.82 
Sin.A (mm2) 0.03 ± 0.01  0.06 ± 0.01  0.02 ± 0.01  0.01 ± 0.01 




















Figure 5.9 - GLN therapy increases bone marrow iron content. Arrow heads 




8-OHdG immunostaining showed distribution throughout the marrow cavity in all samples 
with varying intensities in relation to the bone surface and select osteocytes regions within sickle 
specimens. Within 100 microns from the endosteal surface of the cortical bone, 42.8% (WT) and 
69.5% (SS) of marrow cells were considered significantly damaged by oxidative stress. GLN 
appears to reduce the number of damaged cells in the GLN+ subgroup albeit a smaller population 
of cells present near the surface (Figure 5.10A). The majority of GLN- cells (69.5%) were damaged 
and exhibited a smaller population as well. The amount of oxidative damage appears to lower 
towards the middle of marrow in the cortical shaft. WT population reduces to only 10.6% of the 
marrow cells, and nearly halves for SS mice (Figure 5.10B). The GLN+ marrow cells follow the 
same trend in reduction to only 2.1% of total population being damaged. GLN- subgroup 
distribution remained relatively the same despite being further from the bone surface.  
Within the trabecular region, the distribution of oxidative damaged marrow cells resembles 
that of the endosteal surface 46.6% (WT), 63.6% (SS), 16.2% (GLN+), and 32.4% (GLN-) (Figure 
5.10C). Survey of osteocytes for oxidative stress damage DNA revealed positively stained cells in 
the anterior mid-shaft region of the SS and GLN- tibiae (Figure 5.10D). WT and GLN+ osteocytes 




5.3.6. Osteocyte Gene Expression 
Gene expression collected from osteocyte enriched femoral shafts provided insight into the 
change in osteocyte physiology overtime with respect to SCD and GLN therapy (Figure 5.11). The 
earliest change in relative expression was seen in FGF23 with nearly 18-fold increase at 8 weeks, 
while GLN therapy limited the upregulation to only a 7-fold increase. FGF23 expression is reduced 
to relatively normal levels at 12 and 16 weeks for SS mice, but GLN therapy appears to further 
Figure 5.10 - Spatial distribution of oxidative DNA damage in the bone. Grey box region 
represents thresholded horseradish peroxidase staining intensity of damaged DNA. 
Arrow heads identify positively stained osteocytes.  
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reduce expression up to 10-fold downregulation in GLN+ mice at 12 weeks. The negative regulator 
of bone formation through SOST expression by osteocytes remains unaltered in SS and GLN 
treated mice until 12 weeks where both are increased to 13- and 6-fold, respectively. While 
untreated SS mice exhibit WT-like SOST levels at 16 weeks, GLN therapy leads to a 50- and 22-
fold decrease in relative SOST expression for GLN+ and GLN- mice respectively. GLN therapy 
does not significantly alter the native decline in osteocyte expression of OPG in SS mice until 16 
weeks, with GLN+ mice have an 8-fold decrease as opposed to 4-fold in SS (Figure 5.11C). 
Osteoclastogenic RANKL expression by osteocytes did not stray from the acceptable range of WT 
expression, with the exception of GLN- mice showing 3-fold decrease at 12 weeks (Figure 5.11D). 
5.3.7. Osteoblast Activity + Osteoclastogenesis 
The mean osteogenic alkaline phosphatase (ALP) activity in untreated SS mice is higher 
than controls, but not statistically significant (Figure 5.12). GLN therapy increases ALP levels up 
to 7-fold higher than WT in both GLN+ and GLN- mice at 12 weeks (p<0.05). Elevated osteogenic 
potential of GLN treated mice is lost by 16 weeks. In regard to osteoclastogenesis, the amount of 
GLN in the culture media is inversely related to the number of TRAP positive stained osteoclasts 
(Figure 5.12). Standard culture medium contains 2mM of GLN. Its dilution to 1mM GLN 
generates 75% more osteoclasts, in contrast to GLN supplementation (4mM) which reduces 






Figure 5.11 - Osteocyte gene expression with age in sickle GLN therapy. Grey box 
represents region of WT relative expression. Data outside this region signifies either more 























Figure 5.12 - GLN alters osteoblast and osteoclast activity. GLN+ osteoblasts maintain an 
elevated osteogenic potential. GLN concentration is associated with osteoclast formation. 







Although the FDA approved the utilization of GLN in patients with SCD in 2017, the 
systemic and long-term impacts of the therapy are not fully understood. In this study, we provide 
evidence to support that the Townes transgenic sickle mouse model may be a suitable system to 
further investigate the therapeutic efficacy and mechanism of GLN in SCD. Oral administration 
of GLN recapitulates the increase in blood redox potential (NADH/NADt) that was observed in 
patients with SCD disease by Niihara and colleagues (Niihara et al., 2018, 2016, 2014). Assuming 
the pathology for sickle mice mirrors the human condition, bone quality metrics will provide 
insight at the systemic and local tissue level. 
The most notable impact of GLN therapy was the hindrance of sickle mouse splenomegaly 
and the sudden regression to an untreated phenotype in ~40% of GLN mice at 12 and 16 weeks of 
age. Splenectomies are common practice in the management of acute pain that accompanies 
splenomegaly in SCD, especially in young children (as early as 2 years old) due to splenic 
sequestration of RBC (Al-Salem, 2011). The spleen and liver share the responsibility of removing 
damaged RBC from circulation and recycling the iron for erythropoiesis (Theurl et al., 2016). With 
the removal of the spleen (natural or surgical), the demand is placed solely on the liver and 
increases its overall metabolic activity. However, studies have also shown the spleen hinders 
hepatic regeneration, suggesting that splenectomies may provide more than acute pain alleviation 
(Li et al., 2017). Nonetheless, the spleen and liver are severely damaged and enlarged in SS mice 
and the prevention of hepatosplenomegaly insinuates improved tissue function as supported by the 
increase in liver secretory proteins HPX and IGF-1 with GLN therapy. The rise in plasma HPX 
concentration, which is normally depleted overtime due to excessive hemolysis in SCD, provides 
additional support to combat against heme derived oxidative stress. Exogenous HPX therapy has 
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been shown to reduce the complications of acute kidney injury in sickle mice by retaining iron 
deposition and degradation to the liver (Ghosh et al., 2019, 2013).  Evidence of this phenomena 
may be represented by the reduced population of severe oxidative damage marrow cells in GLN+ 
sickle mice. 
  We have previously reported that IGF-1 deficiency is the predominant reason for 
ineffective sickle cortical bone growth and development (Aim 2). GLN associated IGF-1 
expression contributes to the substantial increase in cortical thickness. Which in turns leads to the 
increase in whole bone stiffness and maximum load resistance of GLN+ tibias. The prolonged 
elevated IGF-1 concentrations in GLN+ mice exceed that of WT controls and may explain the 
difference in cortical thickness at skeletal maturity. The decrease of IGF-1 in the GLN- subgroup 
at 12 and 16 weeks further supports the role IGF-1 plays in cortical thickness and its impact on 
mechanical strength. In the same previous study, testosterone deficiency and the subsequent lack 
of androgen receptor signaling in sickle males failed to promote femoral trabecular growth. 
Surprisingly, GLN therapy increased tibial bone content at 12 weeks without an increase plasma 
testosterone level. This discrepancy may be due to the differences in blood circulation or 
distribution of mechanical forces and the subsequent microarchitectural adaption. Although GLN 
treated sickle mice did not obtain as high of peak trabecular mass as WT mice, they maintained a 
relatively normal trabecular bone volume at skeletal maturity. However, both sickle femurs and 
tibia exhibit reduced trabeculae in the center of the metaphyseal region regardless of treatment 
status.  
The benefit of GLN therapy also extends into altering bone cell physiology. The ex vivo 
culturing of primary osteoblasts suggest that GLN increases sickle osteogenic activity, specifically 
when the naive osteoblast activity decreases with skeletal maturity. However, it does not account 
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for the in vivo pathological environmental factors (ie. inflammation, oxidative stress, hypoxia, etc.) 
that may be influencing sickle bone mineralization or ECM production by these cells (Bala et al., 
2013; Roschger et al., 2008). Previous studies have also shown that osteoclasts are sensitive to 
similar environmental factors, whereas osteoblast activity is typically lowered with inflammation, 
osteoclast activity is bolstered (Banfi et al., 2008; Tanaka et al., 2005). Xiao and colleagues 
demonstrate that amount of osteoclast precursors and basal activity do not vary between sickle and 
control mice when cultured in vitro; suggesting that the microenvironment or intracellular 
signaling is the primary driver for bone resorption (Xiao et al., 2016). Depending on the available 
concentration of GLN circulating through the marrow, GLN therapy may encourage bone 
formation by limiting osteoclastogenesis. In regard to osteocytic regulation of the bone, sickle 
adolescent osteocytes upregulate the expression of FGF-23 and SOST thereby reducing overall 
bone mineralization via osteoblasts. GLN therapy partially rescues mineralization impedance by 
osteocytes but is not able to influence osteocyte regulation of osteoclastogenesis via OPG and 
RANKL.  
Histological survey of the marrow and bone tissue suggest there are spatial differences in 
oxidative DNA damage. Regions near the bone surface (cortical endosteal and trabeculae) have 
the largest population of severe oxidative damage in comparison to the central marrow cavity. The 
vasculature spatial arrangement in the bone may explain the different regions of oxidative damage. 
The main blood supply of long bones is derived from arteries that run parallel with the longitudinal 
axis throughout the central marrow and mineralized tissue, which branch off into medullary 
sinusoids that supply the entire marrow space and ultimately converge into larger veins to exit the 
bone (Ramasamy, 2017). Sinusoids can be categorized into either H or L sinusoids depending on 
as to whether they express high or low amounts of CD31 (also known as Platelet endothelial cell 
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adhesion molecule or PECAM1) and endomucin (Ramasamy et al., 2016, 2014). Type H sinusoids 
reside in actively growing parts of the bone such as the primary spongiosa and the endosteal 
surface. While type L vessels are centrally located within the marrow cavity. The physiological 
roles of type H and L sinusoids are not clear, but studies suggest H vessels may mediate 
angiogenesis during growth (Kusumbe et al., 2014). Previous studies have shown that 
CD31/PECAM1 is associated with the adhesion and transmigration of monocyte/macrophages on 
the endothelium (Muller et al., 1993). While this may be related to the formation osteoclast and 
bone remodeling units in healthy tissue; sickle RBCs have the propensity to interact with adherent 
leukocytes leading to disrupted fluid flow, vaso-occlusion, and ischemic injury derived oxidative 
stress (Turhan et al., 2002).  
With age, type H vessels transition to type L with the loss of CD31/PECAM1 and 
endomucin expression due to HIF1α destabilization (Kusumbe et al., 2016). GLN metabolism is 
essential for the production of α-ketoglutarate, a key intermediary molecule of the Krebs cycle 
that facilitates the degradation of HIF1α; therefore, GLN therapy may reduce type H sinusoids in 
the marrow and the subsequent sickle RBC complications. However, other studies have 
demonstrated that glutaminolysis stabilizes HIF1α expression in tumor cells (Kappler et al., 2017). 
If a similar mechanism is being utilized by the endothelium, the prolonging of type H sinusoids 
could either encourage sickle bone growth or further propagating vaso-occlusive events in the 
vasculature as noted by GLN+ and GLN- phenotypes. Additional studies are needed to determine 
as to whether GLN influences type H and L sinusoidal maturation.  
GLN metabolism may also play a role in the intrinsic material properties of the bone ECM. 
Hydroxyl modification of the collagen precursor, procollagen, is vital for the formation of the triple 
helix structure of collagen. This reaction depends on α-ketoglutarate, oxygen, and ferrous (Fe2+) 
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iron (Gorres and Raines, 2010; Tuderman et al., 1977). Inactive ferric (Fe3+) iron, which is 
normally stored in the bone marrow and reduced to the active ferrous iron form when needed, is 
severely depleted or absent in SCD due to excessive urinary loss (Rao et al., 1983; Washington 
and Boggs, 1975). Prussian blue staining of GLN treated sickle mice revealed a 10-fold increase 
in ferric iron present in the marrow. This may be a beneficial consequence of increased HPX 
bioavailability and its role preventing kidney injury. Alternatively, GLN associated iron may 
indirectly alter osteoblast iron metabolism and mineralization. The release of calcium and 
phosphate ions by osteoblasts is responsible for the formation and propagation of hydroxyapatite 
crystals between the ECM collagen fibrils. However, osteoblasts also express ferroportin 1 
(FPN1), the only known iron exporter in mammals (Xu et al., 2012; Zhao et al., 2014).  In vitro 
studies have shown that labile Fe2+/Fe3+ is able to incorporate into the crystal lattice as a 
substitution for either the calcium or phosphorus of the phosphate ion (Jiang et al., 2002). This in 
turn changes hydroxyapatite crystallinity and inhibits growth (Guggenbuhl et al., 2008; 
Mahachoklertwattana et al., 2003). The elevation of serum iron and hemolytic heme in conjunction 
with disrupted collagen synthesis and mineralization may explain the post yield mechanical 
behavior of sickle and GLN treated mice. 
Overall, the ubiquitous utilization of GLN generates a more global therapeutic effect in 
SCD rather than solely a RBC modality as previously proposed. Based on its relationship with the 
spleen, bone, and the significant increase in systemic secretory proteins, the liver appears to be the 
primary beneficiary of GLN therapy. However, the emergence of the non-responsive GLN 
subgroup and the bone marrow void spaces, is of great concern. While it has been shown that GLN 
is essential for normal liver physiology and regeneration after injury, prolonged excessive GLN 
exposure can promote liver dysfunction and cirrhosis (Cruzat et al., 2018). Further studies are 
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needed to determine what causes GLN unresponsiveness and better understand its impact on sickle 
bone marrow physiology in order to identify which sickle patients are suitable for GLN therapy 



























CHAPTER 6: CONCLUSIONS & FUTURE DIRECTIONS 
Once considered a fatal disease of childhood, more than 95% of patients born today with SCD in 
developed countries survive into adulthood, largely due the advances in medical treatment and 
SCD management. Despite the progress in improving SCD’s prognosis, the life expectancy of 
patients with SCD is shortened by approximately 45 years in the United States (Platt, 1994). While 
there are several experimental cures undergoing clinical trials, a large population of patients will 
most likely not be able to partake in the cure. Despite the increasing number of people living with 
SCD, remarkably, few detailed studies have described the pathological complications within the 
body outside of the vasculature and blood cells. Bone tissue is of particular interest due to its 
relationship with and dependence on nearly every major organ system. Therefore, the objective of 
this thesis was to characterize the pathophysiology of SCD on bone tissue growth and 
development. Our approach utilized the Townes transgenic sickle mouse model to thoroughly 
examine native bone degeneration longitudinally at the macro- and microscopic level, which is 
clinically unfeasible. The theoretical and clinical significance accrued across this thesis has 
addressed the gaps in knowledge regarding (1) the role of sickle RBC hemolysis in tissue 
degeneration, (2) the onset and progression of sickle osteonecrosis, (3) gender differences in sickle 
pathology, (4) the influence of chronic oxidative stress on bone cell physiology, as well as (5) the 
benefits of GLN therapy on sickle bone quality. The findings, conclusions and recommendations 
for future studies drawn from this thesis work are stated in this chapter. 
 
6.1. Aim 1 - The Microarchitecture and Biomechanics of Sickle Bone 
As discussed in Chapter 3, the Townes transgenic mouse model is able to recapitulate the 
current clinical manifestations that are known to occur in SCD, namely cortical thinning and 
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expansion of the marrow cavity. The utilization of microCT allowed for standardized examination 
of sickle bone microarchitecture that has remained consistent regardless of the varying equipment, 
technician, or bone examined. The loss of bone in adult HbSS mice was to be expected, however 
the osteopenia of heterozygous HbAS (trait) was a perplexing surprise due to it largely being 
considered an asymptomatic condition. The development of clinical microCT would provide 
further insight as to whether the bone of sickle trait patients is more at risk for osteopathic 
complications than someone who is not a carrier. Additional studies are needed to address the 
material composition of sickle bone as noted by the ductility of both trait and sickle bone. Raman 
spectroscopy and crystallography studies would be able to provide such insight into mineral and 
ECM composition.  
Further characterization of the axial skeleton is needed to determine if the pathology 
observed within the appendicular skeleton holds true throughout the body. The microarchitecture 
of the vertebrae is of great interest due to the significant difference between WT controls and sickle 
trabecular regions. Lastly, how well does this mouse model translate over to sickle human bone 
pathology? Human SCD consists of several different polymorphisms in addition to the primary 
beta hemoglobin mutation, and growing evidence supports pathological features such as fetal 
hemoglobin composition differ amongst haplotypes and subsequently vary disease severity 
(Gabriel, 2010). Albeit different genetic manipulations, the Berkeley sickle mouse (beta 
hemoglobin knockout) model has been shown to exhibit slightly different pathological 
manifestations than the Townes (“knock-in”) model employed in this study; therefore may serve 
as a proxy for understanding the different sickle haplotypes until the development of more relevant 




6.2. Aim 2 - The Lack of Sexual Dimorphism in Sickle Bone Due to Hormonal Deficiencies 
The relative normalcy of sickle bone morphology and mechanical behavior during 
adolescents and marked osteopenia demonstrated in Chapter 3 (Aim 1) served as the initial 
evidence for a progressive bone degeneration in SCD. However, longitudinal examination of sickle 
bone growth and development in Chapter 4 revealed that the sickle bone pathology of male mice 
is a failure to gain bone. Further analysis suggests the deficiencies in plasma IGF-1 and 
testosterone serve as the cause for cortical thinning and reduced trabecular volume, respectively. 
The reduction in plasma IGF-1 is seen as early as 8 weeks of age but does not manifest in the 
cortical bone until 12 weeks and both the trabeculae and testosterone fail to increase beyond the 
amount present during adolescence. Moreover, this lack of hormonal signaling, prevents the sexual 
dimorphism of bone to be established in SCD. Interestingly, sickle females exhibit similar 
hormonal levels as age and gender matched WT controls. Previous studies have shown that female 
bone growth does not depend on IGF-1 and estrogen signaling like. An increase in cortical and 
trabecular bone mass in adolescent sickle mice is the result of a larger total body mass - a byproduct 
of hepatosplenomegaly and nephromegaly (data not shown). Future studies are needed to identify 
why female mice do not exhibit the cortical or trabecular thinning their male counterparts do. 
Gladwin and colleagues have suggested that estrogen derived nitric oxide increases the antioxidant 
capacity of female patients with SCD, thereby temporarily protecting them from oxidative injury 
(Gladwin et al. 2003). However, mature sickle female mice (24 weeks) have displayed marked 
osteopenia in comparison to WT controls (Xiao et al. 2016). Therefore, extending this study 
beyond developmental phases of bone growth may provide insight into bone remodeling and late 
adulthood aspects of SCD. Finally, a more comprehensive understanding of bone physiology of 
 
101 
sickle female mice may be exploited to address the growing clinical concerns surrounding 
pregnancy, lactation, and menopause in SCD. 
 
6.3. Aim 3 - The Influence of L-Glutamine Therapy on Sickle Bone Growth and Development 
In Chapter 5 the therapeutic mechanism of GLN in SCD was addressed at the systemic and 
bone tissue level. Adolescent assessment of GLN treated mice show that the therapy significantly 
reduced the splenomegaly commonly seen in SCD, which in turn led to an increase in plasma 
concentration of liver derived IGF-1 and cortical bone thickness. GLN therapy may have also 
increased the productivity of osteoblasts and reduced osteoblastogenesis, but more detailed studies 
about the unaccounted signaling (i.e. inflammation) of the microenvironment may have influenced 
bone cell physiology. However, at 12 weeks the splenomegaly returned in 40% of GLN treated 
mice and bone quality followed suit with thinning cortical bone and reduced trabecular content. 
This discrepancy in therapeutic efficacy remains unknown and future studies should seek to 
examine the effects of GLN at the individual level. One limitation of this study was the ad libitum 
delivery of the GLN orally through the drinking water. Although this method of drug delivery was 
chosen due to the aversion of potential esophageal injury and stress from daily oral gavaging for 
months at a time, a more sophisticated and reliable mechanism of delivery may resolve therapeutic 
differences. Additional studies should examine the impact of GLN therapy introduced at varying 
stages of the disease to help identify when it is too late to begin this therapy as well as its ability 
to regress or prevent further tissue degeneration. Histological surveys of the spleen, liver, and 
kidney are necessary to better understand the systemic impact of GLN therapy on the body.    
The increase in HPX in GLN treated mice and the reduced population of damaged bone 
marrow cells highlights the significance of antioxidant therapy in SCD. Follow up studies utilizing 
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mechanism specific drugs (ie. N-acetylcysteine) and tissue targeted modalities should be 
performed to determine whether oxidative stress of the marrow, vasculature or bone cells are the 
predominant pathological culprit of sickle bone pathology. In this study a small population of 
osteocytes with oxidative damaged DNA was localized to the anterior mid-shaft of the tibia. 
Physiologically relevant mechanical testing and modeling of the tibia associate this region with 
elevated tensile stress (source). Avascular necrosis in SCD leads to the collapse of the femoral 
head and fractures in the neck region (source). Typically caused by low impact falls in the elderly, 
femoral neck fractures are more associated with tensile stress than compressive. Radiographic 
scans of the femoral head of sickle patients show reduced mineral within the regions of tensile 
stress. The question then arises, how does SCD related oxidative stress influence the 
mechanotransduction and viability of osteocyte? Mechanical loading and osteocyte response 
studies would help determine this answer. Lastly, a cross section histological analysis would 
provide better insight into cortical bone osteocyte physiology in relation to their spatial distribution 
and mechanical forces, bone remodeling histomorphometry, and surface interactions with 
osteoblasts and osteoclasts. 
 
6.5. Conclusion 
Overall, this dissertation validates the Townes transgenic sickle mouse model is a suitable 
tool to elucidate the native bone pathology of sickle cell disease and evaluate therapeutic 
mechanisms of novel drugs based on the systemic integration of bone physiology. A 
comprehensive understanding of sickle pathophysiology within the context of this model system 
has been used previously for other organ systems, specifically the lung, to develop targeted 
therapies that can address life threatening complications such as acute chest syndrome. With the 
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advancement of healthcare and emergence of novel therapies dedicated to SCD, patients are living 
longer than ever. Bone complications are some of the most common issues for hospitalizations 
with ageing, however it is one of the most under investigated fields in SCD. This work will serve 
as the foundation for the building of a new field of sickle cell research and the collective in-depth 
knowledge of bone and its role in whole body health will be used to create and improve existing 


































TISSUE ISOLATION AND CELL CULTURE PROTOCOLS 
 
A1. BONE TISSUE HARVESTING  
1. Apply betadine solution to hindlimb. 
   
2. Remove skin by making incision a little above the 
ankles. Do not nick the bone just the skin around it. 
 
3. Grab the foot with one hand and use a tweezer with 
the hand. Use tweezer to grab the skin from the 
incision point and pull down to expose the hind leg.  
*Be careful not to sever the foot from the femur.  
4. Cut the skin/fur horizontally across the groin and cut 
the midsection vertically until you reach the chest. 
5. Raise the skin towards the interior. 
6. Remove the abdominal organs and determine the 
mass of liver, kidney, and spleen. 
7. Remove skin around and under the thoracic 
vertebrae.  
*Be careful not to sever the spine. 
 
8. Make an incision in the middle of the hamstring and 
quadriceps muscles to gain access to the pelvic bone. 
9. Use scissors to cut the pelvic bone. Make sure the 
incision is closer to the femur while avoiding the ball 
and socket joint.  
*Cut muscle parallel to the spine to remove hind limb 
from the partial pelvis.  
 
10. Gently twist off (with hands) the pelvic bone from the 
femur to expose the femoral head.  
 
11. Remove the excess muscle tissue from hind limb 
without fracturing the femur, tibia, and fibula with 
scissors. Use Kim wipe to pull off remaining excess 
tissue.  
12. Place hind limb in a 50mL conical tube 
with a fixative (10% formalin).  








A2. PRIMARY OSTEOBLAST ISOLATION AND CULTURE 
 
1. Place excised femur in sterile saline solution 
2. Cut the ends with sterile scalpel/scissors 
3. Place bone in 0.5mL centrifuge tube with hole made by 
18-gauge needle  
4. Place 0.5mL centrifuge tube inside 1.5mL centrifuge 
tube and seal with parafilm 
5. Centrifuge tubes for 5 minutes at 1500 rpm 
6. Remove 0.5mL interior tube with cortical shaft 
*Shaft can be snapped frozen in liquid nitrogen for 
osteocyte gene expression or processed further for 
osteocyte isolation 
7. Resuspend pellet in 1mL of aMEM medium 
8. Dilute cells 1:100 and count 
9. Plate cells in 6 well-plate at 3x106 cell/well in 
osteogenic media  












A3. PRIMARY OSTEOCLASTOGENESIS CULTURE 
 
1. After plating osteoblast, take the remaining 
marrow cells and plate them in 10mm dish 
containing 10mL of osteoclast medium 
2. Next day, collect non-attached cell (supernatant) 
from dish and put into 15mL tube 
3. Spin cells for 5 mins 1500 rpm 
4. Aspirate supernatant,  
5. Add 5mL of cold RBC lysing solution 
6. Rock for ~10mins at room temperature until 
liquid is clear red 
7. Centrifuge at 4C for 10 minutes at 250xg 
8. Aspirate and resuspend pellet in 1 mL of 
osteoclastogenic media 
9. Plate cells in 96-well plate at 0.15x106 
cells/well 
OSTEOGENIC MEDIA 
MEDIA FINAL CONC. 
aMEM 1x 
Pencillin/Streptomycin 1% 
Fetal Calf Serum 10% 
Dexamethasone 8 mM 
B-glycerol phosphate 10 mM 
Ascorbic Acid 50 ug/mL 




Millipore Water 100mL 
OSTEOCLAST MEDIA 
MEDIA FINAL CONC. 
aMEM 1x 
Pencillin/Streptomycin 1% 
Fetal Calf Serum 10% 
M-CSF 4 uL/mL 




BIOCHEMICAL ASSAYS AND PROTOCOLS 
 
B1. NADH/NADTOTAL REDOX POTENTIAL  
*Adapted from EnzyChrom NAD+/NADH Assay Kit (E2ND-100) 
 
Sample Preparation.  
1. Homogenize 20 uL of blood sample in a 1.5 mL Eppendorf tube with either 100 µL NAD 
extraction buffer for NAD determination or 100 µL NADH extraction buffer for NADH 
determination.  
2. Heat extracts at 60°C for 5 min and then add 20 µL Assay Buffer and 100 µL of the 
opposite extraction buffer to neutralize the extracts.  
3. Briefly vortex and spin the samples down at 14,000 rpm for 5 min.  
4. Use supernatant for NAD/NADH assays.  
*Determination of both NAD and NADH concentrations requires extractions from two 
separate samples. 
Calibration Curve.  
5. Prepare 500 µL 10 µM NAD Premix by mixing 5 µL 1 mM Standard and 495 µL 
distilled water.  
6. Dilute standard as follows. 
No Premix + H2O NAD (µM) 
1 100 µL + 0 µL 10 
2 60 µL + 40 µL 6 
3 30 µL + 70 µL 3 
4 0 µL + 100 µL 0 
 
7. Transfer 40 µL standards into wells of a clear flat-bottom 96-well plate.  
8. Add 40 µL of each sample in separate wells.  
9. For each well of reaction, prepare Working Reagent by mixing 60 µL Assay Buffer, 1 µL 
Enzyme A, 1 µL Enzyme B, 14 µL Lactate and 14 µL MTT.  
10. Add 80 µL Working Reagent per well quickly. Tap plate to mix briefly and thoroughly.  
11. Read optical density (OD0) for time “zero” at 565 nm (520-600nm) and OD15 after a 15-
min incubation at room temperature.  
Analysis 
12. First compute the ΔOD for each standard and sample by subtracting OD0 from OD15.  
13. Plot the standard ΔOD’s and determine the slope. The NADH and NAD concentration of 






• ΔODSAMPLE and ΔODBLANK are the change in optical density values of the Sample and 
Blank (STD 4) respectively. Slope is the slope of the standard curve and n is the 
dilution factor (if necessary). Note: If the sample ΔOD values are higher than the 
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ΔOD value for the 10 µM standard, dilute sample in distilled water and repeat this 
assay. Multiply the results by the dilution factor. 
B2. OSTEOGENIC POTENTIAL ALKALINE PHOSPHATASE ASSAY  
 
Materials 
• Disodium pi-nitrophenylphate (PNPP) (20mM) 
• 2-amino-w-methyl-l-propanol (AMP) (1.5M) 
• MgCl2 (100mM) 
• NaOH (10N) 
• Tris-hydroxymethylaminomethane (Tris) Basic form (0.1M, pH 7.5) 
• Triton X-100 (100mL) 
 
Working Solutions 
Cell Lysis Buffer (pH 7.5) ALP Assay Mix (pH 10.3) Stop Solution 
10mM Tris-HCl 2 mM PNPPP 5N NaOH 
0.1% Triton X-100 0.15M AMP  
Distilled H2O 2mM MgCl2  
 Distilled H2O  
 
ALP Assay Procedure 
1. Perform after 3 weeks of osteoblast culturing 
2. Aspirate cell media and wash cells 3X with PBS 
3. Add 0.5mL of lysis buffer and mechanically lysis cells with scrapper 
4. Add 10uL of cell lysis suspension to microcentrifuge tubes 
5. Initiate reaction by adding 200uL of substrate solution and incubate in 37°C water for 10 
minutes 
6. Stop reaction by adding 0.16mL of 5N NaOH and remove from water bath 
7. Transfer 100uL of reaction solution to 96 well plate 
8. Read OD of sample at 410nM 
9. Calculations 
(𝑂𝐷𝑠𝑎𝑚𝑝𝑙𝑒 − 𝑂𝐷𝑏𝑙𝑎𝑛𝑘) ∗ 0.05714
∆𝑚𝑖𝑛𝑢𝑡𝑒𝑠 = 𝑢𝑚𝑜𝑙	𝑃𝑁𝑃/𝑚𝑖𝑛 
 

















B3. OSTEOCLAST TRAP STAININING 
*Adapted from Sigma-Aldrich Acid Phosphate Leukocyte (Procedure No. 387) 
 
1. Prewarm sufficient deionized water for a day’s use to 37°C. Check temperature before 
use. 
2. Add 100 uL of fixative (e.g. 10% formalin) to 96-well plate for 30 seconds 
3. Decant and wash with DI water 3X 
4. Add 0.5 ml Fast Garnet GBC Base Solution and 0.5 ml Sodium Nitrite Solution to test 
tube. Mix by gentle inversion for 30 seconds. Let stand 2 minutes. 
5. Create Solution A and B in 50 mL conical tubes. 
 
 Solution A Solution B 
Deionized Water 45 mL 45 mL 
Fast Garnet Solution (from step 3) 1.0 mL 1.0 mL 
Naphthol AS-BI Phosphate 0.5 mL 0.5 mL 
Acetate Solution 2.0 mL 2.0 mL 
Tartare Solution - 1.0 mL 
 
6. Warm solutions in jars to 37°C in water bath. 
7. Add 100uL of solution A or B to well plates and incubate for 1 hour in 37°C water bath 
protected from light. 
8. Rinse slides thoroughly in deionized water, then counterstain 2 minutes in Hematoxylin 
Solution. 
9. Rinse several minutes in alkaline tap water to blue nuclei.  
10. Air dry and evaluate microscopically. 























B3. OSTEOCYTE RNA ISOLATION AND RT-PCR 
 
RNA Isolation 
1. Pour liquid nitrogen into mortar and pestel 
2. Add bone and pulverize after liquid nitrogen evaporates 
3. Add 1mL of Trizol 
4. Scoop sample into Qiashredder 
5. Allow sample to thaw and centrifuge for 2 min at 13000 RPM at 4C 
6. Remove (purple) filter and add 200uL chloroform (per 1mL Trizol) 
7. Vortex for 15 seconds 
8. Let sit for 15 minutes at room temperature 
9. Centrifuge for 15 minutes at 13000 RPM at 4C 
10. Remove 650uL of aqueous layer (clear) and transfer into new tube 
11. Add 650uL of 70% ethanol to new tube 
12. Add 650uL of solution to RNeasy tube (pink filter) 
13. Centrifuge for 15 seconds and discard flow through 
Repeat steps 12 & 13 with remaining solution   
14. Add 650uL RW1 to center of column of pink filter, centrifuge for 15 seconds, and 
discard flow through 
15. Add 500uL RPE buffer to center of column of pink filter, centrifuge for 15 seconds, and 
discard flow through 
16. Add 500uL RPE buffer to center of column of pink filter, centrifuge for 2 minutes, and 
discard flow through 
17. Transfer pink filter to new collection tube 
18. Add 30uL of RNAse free water to center of filter column 
19. Centrifuge for 1 minute at top speed  
20. Use nandodrop to measure RNA concentration and purity 260/280 
21. Freezer sample in -80C or continue to reverse transcription 
 
Quantitect Reverse Transcription 
1. Thaw template RNA on ice. Thaw gDNA Wipeout Buffer, Quantiscript Reverse 
Transcriptase, Quantiscript RT Buffer, RT Primer Mix, and RNase-free water at room 
temperature (15–25°C). Mix each solution by flicking the tubes. Centrifuge briefly to 
collect residual liquid from the sides of the tubes, and then store on ice. 
2. Prepare the genomic DNA elimination reaction on ice for 1ug of Template RNA 
according to Table below. Mix and then store on ice.  
Note: If setting up more than one reaction, prepare a volume of master mix 10% greater 
than that required for the total number of reactions to be performed. Then distribute the 
appropriate volume of master mix into individual tubes followed by each RNA sample. 




3. Incubate for 2 min at 42°C. Then place immediately on ice. 
Note: Do not incubate at 42°C for longer than 10 min. 
4. Prepare the reverse-transcription master mix on ice according to Table 2. 
Mix and then store on ice. The reverse-transcription master mix contains all components 
required for first-strand cDNA synthesis except template RNA. 
Note: If setting up more than one reaction, prepare a volume of master mix 10% greater 
than that required for the total number of reactions to be performed.  
Note: The protocol is for use with 10 pg to 1 μg RNA. If using >1 μg RNA, scale up the 
reaction linearly. For example, if using 2 μg RNA, double the volumes of all reaction 
components for a final 40 μl reaction volume. 
 
 
5. Add template RNA from step 3 (14 μl) to each tube containing reverse-transcription 
master mix. 
Mix and then store on ice. 
6. Incubate for 15 min at 42°C. 
In some rare cases (e.g., if the RT-PCR product is longer than 200 bp or if analyzing 
RNAs with a very high degree of secondary structure), increasing the incubation time up 
to 30 min may increase cDNA yields. 
7. Incubate for 3 min at 95°C to inactivate Quantiscript Reverse Transcriptase. 
8. Add an aliquot of each finished reverse-transcription reaction to real-time PCR mix  
Store reverse-transcription reactions on ice and proceed directly with real-time PCR, or 




RT2 PCR Array Protocol 
1. Dilute stock cDNA to 0.2 ug in 26 uL of RNA-ase free water in Nuclease-free 
microcentrifuge tube 
Note:  5.2 uL of stock CDNA + 20.8 uL of RNA-ase free water  
2. Briefly centrifuge the RT2 SYBR Green Mastermix (10–15 s) to bring the contents to the 
bottom of the tube.  
Note: As the RT2 SYBR Green Mastermix contains HotStart DNA Taq Polymerase that 
is active only after heat activation, reactions can be prepared at room temperature (15–
25°C). 
3. Prepare the PCR components mix in a 5 ml tube or a loading reservoir depending on the 
RT2 Profiler PCR Array format, as described in table below. 
Array Format: Master Mix per bone (24 wells) 
2x RT2 SYBR Green Mastermix 337 uL 
cDNA synthesis reaction 26 uL 
RNase-free water 312 uL 
Total Volume 675 uL 
 
4. Dispense the PCR components mix into the RT2 Profiler PCR Array depending on the 
RT2 Profiler PCR Array format, as described below. 
Note: Change pipet tips following each pipetting step to avoid cross contamination 
between the wells. 
• Carefully remove the RT2 Profiler PCR Array from its sealed bag. 
• Optional: If the PCR components mix is in a tube, transfer to a loading reservoir 
• Add 25 μl PCR components mix to each well of the RT2 Profiler PCR Array 
using an 8-channel pipettor, or a 12-channel pipettor using only 8 tips.  
NOTE: One bone/sample = 24 wells. See plate setup below  
 
5. Carefully, tightly seal the RT2 Profiler PCR Array with Optical Adhesive Film 
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6. Centrifuge for 1 min at 1000 g at room temperature (15–25°C) to remove bubbles. 
Visually inspect the plate from underneath to ensure no bubbles are present in the wells. 
Note: The presence of bubbles in the wells interferes with results. 
7. Place the RT2 Profiler PCR Array on ice while setting up the PCR cycling program. 
Note: The RT2 Profiler PCR Array containing PCR components mix may be stored at –
15 to –30°C wrapped in aluminum foil for up to one week if desired. 
8. Program the real-time cycler according to Table 4, 5, or 6, depending on the real-time 
cycler used. If prompted by your cycler software, select “Absolute Quantitation” to 
begin. 
 
9. Start Run 
































C1. OXIDATIVE DNA DAMAGE INTENSITY  
 
1. Open desire image in ImageJ 
2. Select “Image” > “Type” > “8-bit” 
3. Select “Image” > “Adjust” > “Threshold” 
4. Select “Analyze” > “Set Measurements”  
 
5. Select “Analyze” > “Analyze Particles…” 
  
6. Average the intensities of 6-8 random 
intracellular regions to determine background intensity 
7. Subtract the individual marrow cell intensity from the mean background intensity of the 
image. 
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